U.S. patent application number 13/350237 was filed with the patent office on 2012-05-10 for polymer conjugates with decreased antigenicity, methods of preparation and uses thereof.
This patent application is currently assigned to Mountain View Pharmaceuticals, Inc.. Invention is credited to Alexa L. MARTINEZ, Mark G.P. Saifer, Merry R. Sherman, L. David Williams.
Application Number | 20120114742 13/350237 |
Document ID | / |
Family ID | 46123506 |
Filed Date | 2012-05-10 |
United States Patent
Application |
20120114742 |
Kind Code |
A1 |
MARTINEZ; Alexa L. ; et
al. |
May 10, 2012 |
Polymer Conjugates with Decreased Antigenicity, Methods of
Preparation and Uses Thereof
Abstract
Methods are provided for the preparation of conjugates of a
variety of bioactive components, especially proteins, with
water-soluble polymers (e.g., poly(ethylene glycol) and derivatives
thereof), which conjugates have reduced antigenicity and
immunogenicity compared to similar conjugates prepared using
poly(ethylene glycol) containing a methoxyl or another alkoxyl
group. The invention also provides conjugates prepared by such
methods, compositions comprising such conjugates, kits containing
such conjugates or compositions and methods of use of the
conjugates and compositions in diagnostic and therapeutic
protocols.
Inventors: |
MARTINEZ; Alexa L.; (San
Jose, CA) ; Sherman; Merry R.; (San Carlos, CA)
; Saifer; Mark G.P.; (San Carlos, CA) ; Williams;
L. David; (Fremont, CA) |
Assignee: |
Mountain View Pharmaceuticals,
Inc.
Menlo Park
CA
|
Family ID: |
46123506 |
Appl. No.: |
13/350237 |
Filed: |
January 13, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10669597 |
Sep 25, 2003 |
8129330 |
|
|
13350237 |
|
|
|
|
10317092 |
Dec 12, 2002 |
|
|
|
10669597 |
|
|
|
|
60414424 |
Sep 30, 2002 |
|
|
|
Current U.S.
Class: |
424/450 ;
424/178.1; 424/85.1; 424/85.2; 424/85.4; 424/94.3; 435/188;
514/1.1; 514/13.7; 514/15.2; 514/15.7; 514/16.4; 514/17.7;
514/17.8; 514/17.9; 514/19.4; 514/19.5; 514/19.6; 514/2.3; 514/2.4;
514/20.9; 514/3.3; 514/3.7; 514/3.8; 514/4.3; 514/4.6; 514/7.6;
514/7.7; 514/8.5; 514/8.8; 514/8.9; 514/9.1; 514/9.5; 514/9.6;
530/300; 530/350; 530/351; 530/362; 530/380; 530/381; 530/391.1;
530/395; 530/399; 549/510; 568/492 |
Current CPC
Class: |
A61P 3/00 20180101; A61K
31/685 20130101; C12N 7/00 20130101; A61P 9/00 20180101; C08G
65/3356 20130101; A61P 1/16 20180101; A61P 9/12 20180101; A61P
31/04 20180101; A61P 31/18 20180101; C08G 65/3332 20130101; C12Y
107/03003 20130101; A61P 31/00 20180101; A61P 31/10 20180101; C08G
65/3322 20130101; A61K 9/1271 20130101; A61P 25/00 20180101; A61P
35/00 20180101; A61K 38/44 20130101; A61K 31/23 20130101; A61P
31/12 20180101; A61P 25/28 20180101; A61K 35/76 20130101; A61K
47/60 20170801; A61K 47/646 20170801; A61P 33/00 20180101; A61P
35/02 20180101; A61K 38/00 20130101 |
Class at
Publication: |
424/450 ;
530/300; 530/350; 530/395; 435/188; 530/380; 530/399; 530/362;
530/391.1; 530/381; 530/351; 549/510; 424/94.3; 424/178.1;
424/85.4; 424/85.2; 514/7.7; 424/85.1; 514/7.6; 514/1.1; 514/20.9;
514/15.2; 514/13.7; 514/9.6; 514/9.1; 514/8.8; 514/8.9; 514/8.5;
514/9.5; 514/2.3; 514/17.7; 514/16.4; 514/15.7; 514/19.5; 514/19.4;
514/19.6; 514/2.4; 514/3.7; 514/3.3; 514/4.6; 514/3.8; 514/4.3;
514/17.8; 514/17.9; 568/492 |
International
Class: |
A61K 9/127 20060101
A61K009/127; C07K 14/00 20060101 C07K014/00; C12N 9/96 20060101
C12N009/96; C07K 14/435 20060101 C07K014/435; C07K 14/005 20060101
C07K014/005; C07K 14/575 20060101 C07K014/575; C07K 14/52 20060101
C07K014/52; C07K 14/475 20060101 C07K014/475; C07K 14/76 20060101
C07K014/76; C07K 16/00 20060101 C07K016/00; C07K 14/745 20060101
C07K014/745; C07K 14/485 20060101 C07K014/485; C07K 14/50 20060101
C07K014/50; C07K 14/495 20060101 C07K014/495; C07K 14/51 20060101
C07K014/51; C07K 14/505 20060101 C07K014/505; C07K 14/54 20060101
C07K014/54; C07K 14/555 20060101 C07K014/555; C07K 14/525 20060101
C07K014/525; C07D 305/14 20060101 C07D305/14; A61K 38/54 20060101
A61K038/54; A61K 39/395 20060101 A61K039/395; A61K 38/21 20060101
A61K038/21; A61K 38/20 20060101 A61K038/20; A61K 38/18 20060101
A61K038/18; A61K 38/19 20060101 A61K038/19; A61K 38/00 20060101
A61K038/00; A61K 38/14 20060101 A61K038/14; A61K 38/38 20060101
A61K038/38; A61K 38/36 20060101 A61K038/36; A61K 38/22 20060101
A61K038/22; A61K 38/30 20060101 A61K038/30; A61P 31/00 20060101
A61P031/00; A61P 25/00 20060101 A61P025/00; A61P 3/00 20060101
A61P003/00; A61P 9/00 20060101 A61P009/00; A61P 9/12 20060101
A61P009/12; A61P 35/00 20060101 A61P035/00; A61P 35/02 20060101
A61P035/02; A61P 31/04 20060101 A61P031/04; A61P 31/12 20060101
A61P031/12; A61P 31/10 20060101 A61P031/10; A61P 33/00 20060101
A61P033/00; A61P 31/18 20060101 A61P031/18; A61P 1/16 20060101
A61P001/16; A61P 25/28 20060101 A61P025/28; C07C 45/00 20060101
C07C045/00; C07K 2/00 20060101 C07K002/00 |
Claims
1. A conjugate comprising one or more bioactive components
covalently attached to at least one linear or branched polyalkylene
glycol, wherein said polyalkylene glycol does not comprise an
alkoxyl group at any terminus and said polyalkylene glycol is
attached to a single bioactive component at a single site on the
polyalkylene glycol.
2. The conjugate of claim 1, wherein said conjugate is reduced or
substantially reduced in antigenicity compared to a conjugate
comprising the same bioactive component(s) linked at the same site
or sites on the bioactive component(s) to the same number of
polyalkylene glycols of the same size and linear or branched
structure containing one or more terminal alkoxyl groups.
3. The conjugate of claim 1, wherein said linear or branched
polyalkylene glycol is selected from the group consisting of a
poly(ethylene glycol) and a copolymer of ethylene oxide and
propylene oxide.
4. The conjugate of claim 3, wherein said linear or branched
polyalkylene glycol is a poly(ethylene glycol) ("PEG").
5. The conjugate of claim 1, wherein the attachment of said
polyalkylene glycol to said bioactive component(s) is carried out
using a reactive derivative of at least one polyalkylene glycol
selected from the group consisting of linear dihydroxyPEGs ("PEG
diols"), hydroxyPEG-monoacetals and hydroxyPEG-monoacids.
6. The conjugate of claim 1, wherein the attachment of said
polyalkylene glycol to said bioactive component(s) is carried out
using a reactive derivative of hydroxyPEG selected from the group
consisting of a monoaldehyde, a monoester of a monoacid, a
monoamine, a monothiol, a monodisulfide, a monobromophenyl
carbonate, a monochlorophenyl carbonate, a monofluorophenyl
carbonate, a mononitrophenyl carbonate, a monocarbonylimidazole, a
monohydrazide, a monocarbazate, a monoiodoacetamide, a
monomaleimide, a monoorthopyridyl disulfide, a monooxime, a
monophenyl glyoxal, a monothiazolidine-2-thione, a monothioester, a
monotriazine and a monovinylsulfone.
7. The conjugate of claim 1, wherein said polyalkylene glycol has a
molecular weight of from about 1,000 Daltons (1 kDa) to about
100,000 Daltons (100 kDa).
8. The conjugate of claim 7, wherein said polyalkylene glycol has a
molecular weight of from about 2 kDa to about 60 kDa.
9. The conjugate of claim 8, wherein said polyalkylene glycol has
two branches, each with a molecular weight of from about 2 kDa to
about 30 kDa.
10. The conjugate of claim 9, wherein said polyalkylene glycol has
two branches, each with a molecular weight of from about 5 kDa to
about 20 kDa.
11. The conjugate of claim 8, wherein said polyalkylene glycol has
a molecular weight of from about 10 kDa to about 20 kDa.
12. The conjugate of claim 11, wherein said polyalkylene glycol has
a molecular weight of about 12 kDa.
13. The conjugate of claim 8, wherein said polyalkylene glycol has
a molecular weight of from about 18 kDa to about 60 kDa.
14. The conjugate of claim 13, wherein said polyalkylene glycol has
a molecular weight of from about 18 kDa to about 22 kDa.
15. The conjugate of claim 14 wherein said polyalkylene glycol has
a molecular weight of about 20 kDa.
16. The conjugate of claim 13, wherein said polyalkylene glycol has
a molecular weight of about 27 kDa to about 33 kDa.
17. The conjugate of claim 1, wherein said conjugate comprises from
about one to about 100 strands of said polyalkylene glycol.
18. The conjugate of claim 17, wherein said conjugate comprises
from about one to about five strands of said polyalkylene
glycol.
19. The conjugate of claim 18, wherein said conjugate comprises
about one or about two strands of said polyalkylene glycol.
20. The conjugate of claim 17, wherein said conjugate comprises
from about five to about 100 strands of said polyalkylene
glycol.
21. The conjugate of claim 1, wherein said polyalkylene glycol is
selected from the group consisting of a monohydroxyPEG-acid and a
dihydroxyPEG-acid, such as dihydroxyPEG-lysine.
22. The conjugate of claim 1, wherein said polyalkylene glycol, if
linear, has a hydroxyl group at the terminus that is not attached
to the bioactive component(s) ("the distal terminus") or, if
branched, has a hydroxyl group at every distal terminus.
23. The conjugate of claim 5, wherein said polyalkylene glycol is a
reactive derivative of said linear dihydroxyPEG.
24. The conjugate of claim 5, wherein said polyalkylene glycol is a
reactive derivative of said hydroxyPEG-monocarboxylic acid.
25. The conjugate of claim 1, wherein said bioactive component is
selected from the group consisting of a peptide, a protein, a
glycoprotein, an organic compound, an amine-containing compound, a
carboxyl-containing compound, a hydroxyl-containing compound and a
thiol-containing compound.
26. The conjugate of claim 25, wherein said bioactive component is
selected from the group consisting of a peptide, a protein and a
glycoprotein.
27. The conjugate of claim 26, wherein said peptide or protein or
glycoprotein is selected from the group consisting of an enzyme, a
serum protein, a serum glycoprotein, a blood cell protein, a
pigmentary protein, hemoglobin, a viral protein, a peptide hormone,
a protein hormone, a glycoprotein hormone, a hypothalamic releasing
factor, a cytokine, a growth factor and peptides and proteins and
glycoproteins that mimic or function as antagonists of any of the
foregoing group.
28. The conjugate of claim 27, wherein said serum protein is
selected from the group consisting of an albumin, an
immunoglobulin, a blood clotting factor and peptides and proteins
and glycoproteins that mimic or function as antagonists of any of
the foregoing serum proteins.
29. The conjugate of claim 27, wherein said peptide hormone or
protein hormone or glycoprotein hormone is selected from the group
consisting of an antidiuretic hormone, chorionic gonadotropin,
luteinizing hormone, follicle-stimulating hormone, insulin,
prolactin, a somatomedin, growth hormone, thyroid-stimulating
hormone, a placental lactogen and peptides and proteins and
glycoproteins that mimic or function as antagonists of any of the
foregoing hormones.
30. The conjugate of claim 27, wherein said growth factor is
selected from the group consisting of a colony-stimulating factor,
an epidermal growth factor, a fibroblast growth factor, an
insulin-like growth factor, a transforming growth factor, a
platelet-derived growth factor, a nerve growth factor, a hepatocyte
growth factor, a neurotrophic factor, a ciliary neurotrophic
factor, a brain-derived neurotrophic factor, a glial-derived
neurotrophic factor or a bone morphogenic peptide and peptides and
proteins and glycoproteins that mimic or function as antagonists of
any of the foregoing growth factors.
31. The conjugate of claim 27, wherein said cytokine is selected
from the group consisting of erythropoietin, a lymphokine, an
interleukin, an interferon, a tumor necrosis factor, a leukemia
inhibitory factor and thrombopoietin, and peptides and proteins and
glycoproteins that mimic or function as antagonists of any of the
foregoing cytokines.
32. The conjugate of claim 27, wherein said enzyme is selected from
the group consisting of a carbohydrate-specific enzyme, a
proteolytic enzyme, an oxidoreductase, a transferase, a hydrolase,
a lyase, an isomerase and a ligase.
33. The conjugate of claim 32, wherein said oxidoreductase enzyme
is a uricase.
34. The conjugate of claim 32, wherein said proteolytic enzyme is a
plasminogen activator.
35. The conjugate of claim 26, wherein said peptide, protein or
glycoprotein is an allergen.
36. The conjugate of claim 1, wherein said bioactive compound is a
taxane or a derivative thereof.
37. The conjugate of claim 1, wherein said bioactive compound is an
antibiotic or a derivative thereof.
38. A pharmaceutical composition comprising the conjugate of claim
1 and a pharmaceutically acceptable excipient or carrier.
39. A method of preventing, diagnosing, or treating a physical
disorder in an animal, comprising the administration to said animal
of an effective amount of the conjugate of claim 1 or the
composition of claim 38.
40. The method of claim 39, wherein said animal is a mammal.
41. The method of claim 40, wherein said mammal is a human.
42. The method of claim 39, wherein said physical disorder is
selected from the group consisting of a cancer, arthritis, an
infectious disease, a genetic disorder, a neurological disorder, a
metabolic disorder, an enzymatic disorder, a cardiovascular disease
and hypertension.
43. The method of claim 42, wherein said cancer is selected from
the group consisting of a breast cancer, a uterine cancer, an
ovarian cancer, a prostate cancer, a testicular cancer, a lung
cancer, a leukemia, a lymphoma, a colon cancer, a gastrointestinal
cancer, a pancreatic cancer, a bladder cancer, a kidney cancer, a
bone cancer, a neurological cancer, a head and neck cancer, a skin
cancer and other carcinomas, sarcomas, adenomas and myelomas.
44. The method of claim 42, wherein said infectious disease is
selected from the group consisting of a bacterial disease, a fungal
disease, a viral disease and a parasitic disease.
45. The method of claim 44, wherein said viral disease is selected
from the group including HIV/AIDS and hepatitis.
46. The method of claim 42, wherein said genetic disorder is
selected from the group consisting of amyotrophic lateral
sclerosis, cystic fibrosis, Gaucher's disease, hemophilia and other
inherited blood disorders, Pompe's disease and severe combined
immunodeficiency disease ("SCID").
47. The method of claim 42, wherein said neurological disorder is
selected from the group including Alzheimer's disease and multiple
sclerosis.
48. The method of claim 39, wherein said administration is
parenteral.
49. The method of claim 48, wherein said parenteral administration
is intravenous.
50. The method of claim 39, wherein said administration is
oral.
51. The method of claim 39, wherein said administration is
topical.
52. The method of claim 39, wherein said administration is by
inhalation.
53. The method of claim 39, wherein said administration is
rectal.
54. A method of producing a conjugate between a bioactive compound
and a polyalkylene glycol activated at only one terminus ("a
monoactivated polyalkylene glycol"), comprising: (a) obtaining a
polyalkylene glycol that does not contain any end group that is a
stably linked alkoxyl group; (b) optionally, prior to the
conversion of the polyalkylene glycol of step (a) to a
monofunctionally activated polyalkylene glycol, protecting all
except one of the end groups by the addition of one or more
removable blocking groups, such as t-butoxyl group(s), aryloxyl
group(s) or triphenylmethyl group(s) ("trityl group(s)"); (c)
producing a monofunctionally activated derivative of said
polyalkylene glycol by reacting said polyalkylene glycol with a
derivatizing compound or compounds under conditions such that said
polyalkylene glycol is derivatized with a single derivatizing group
at an end that does not contain said removable blocking group or
groups; (d) if a blocking group was added to protect the end
group(s), as described in step (b) above, removing said blocking
group, in one or more steps, without removing the activating group
attached as described in step (c) above, to produce a
monofunctionally activated polyalkylene glycol wherein the distal
terminus or distal termini are hydroxyl groups; and (e) contacting
said monofunctionally activated polyalkylene glycol with at least
one bioactive component, under conditions that favor the covalent
binding of said monofunctionally activated polyalkylene glycol to
said bioactive component, or (f) Alternatively, performing step (e)
prior to performing step (d).
55. The method of claim 54, wherein said derivatizing group is
selected from the group consisting of an aldehyde and a carboxyl
group.
56. The method of claim 54, wherein said blocking group is selected
from the group consisting of a trityl group, an aryloxyl group and
a t-butoxyl group.
57. A method for separating a linear monohydroxyPEG-monoaldehyde
from the corresponding PEG-dialdehyde comprising: (a) converting
all hydroxyl groups on the PEG-aldehyde to trityl derivatives; (b)
separating monotritylPEG-monoaldehyde from the PEG-dialdehyde and
any ditritylPEG by reversed-phase chromatography, and (c)
converting the monotritylPEG-monoaldehyde to
monohydroxyPEG-monoaldehyde by hydrolytic removal of the trityl
group in an acidic medium.
58. The method of claim 57, wherein said aldehyde is, or said
dialdehydes are, in the form of acetal derivatives.
59. A conjugate produced by the method of claim 54.
60. The conjugate of claim 59, wherein said conjugate is reduced or
substantially reduced in antigenicity compared to a conjugate
comprising the same bioactive component linked at the same site or
sites on the bioactive component to the same number of molecules of
polyalkylene glycol of the same size and linear or branched
structure that contain an alkoxyl group at the distal terminus, if
the polyalkylene glycol is linear, or contain two or more alkoxyl
groups at the distal termini, if the polyalkylene glycol is
branched.
61. The conjugate of claim 59, wherein said polyalkylene glycol is
selected from the group consisting of a poly(ethylene glycol) and a
copolymer of ethylene oxide and propylene oxide.
62. The conjugate of claim 59, wherein the polyalkylene glycol
component is selected from the group consisting of a linear
poly(ethylene glycol) and a branched poly(ethylene glycol).
63. The conjugate of claim 59, wherein each said polyalkylene
glycol has a molecular weight of from about 1 kDa to about 100
kDa.
64. The conjugate of claim 63, wherein said polyalkylene glycol has
a molecular weight of from about 2 kDa to about 60 kDa.
65. The conjugate of claim 64, wherein said polyalkylene glycol has
two branches, each with a molecular weight of from about 2 kDa to
about 30 kDa.
66. The conjugate of claim 65, wherein said polyalkylene glycol has
two branches, each with a molecular weight of from about 5 kDa to
about 20 kDa.
67. The conjugate of claim 64, wherein said polyalkylene glycol has
a molecular weight of from about 10 kDa to about 20 kDa.
68. The conjugate of claim 67, wherein said polyalkylene glycol has
a molecular weight of about 12 kDa.
69. The conjugate of claim 64, wherein said polyalkylene glycol has
a molecular weight of from about 18 kDa to about 60 kDa.
70. The conjugate of claim 69, wherein said polyalkylene glycol has
a molecular weight of from about 18 kDa to about 22 kDa.
71. The conjugate of claim 70, wherein said polyalkylene glycol has
a molecular weight of about 20 kDa.
72. The conjugate of claim 69, wherein said polyalkylene glycol has
a molecular weight of about 27 kDa to about 33 kDa.
73. The conjugate of claim 59, wherein said conjugate comprises
from one to about 100 strands of said polyalkylene glycol.
74. The conjugate of claim 73, wherein said conjugate comprises
from about one to about five strands of said polyalkylene
glycol.
75. The conjugate of claim 74, wherein said conjugate comprises
about one or about two strands of said polyalkylene glycol.
76. The conjugate of claim 73, wherein said conjugate comprises
about five to about 100 strands of said polyalkylene glycol.
77. The conjugate of claim 59, wherein the monofunctionally
activated polyalkylene glycol used in the synthesis of said
conjugate is selected from the group consisting of a
hydroxyPEG-monoaldehyde and a reactive ester of a
hydroxyPEG-monoacid.
78. The conjugate of claim 59, wherein the monofunctionally
activated polyalkylene glycol used in the synthesis of said
conjugate has a hydroxyl group at its distal terminus, if it is
linear, or has a hydroxyl group at every distal terminus, if it is
branched.
79. The conjugate of claim 59, wherein the monofunctionally
activated polyalkylene glycol used in its synthesis is derived from
a linear dihydroxyPEG.
80. The conjugate of claim 59, wherein the bioactive component is
selected from the group consisting of a peptide, a protein, a
glycoprotein, an organic compound, an amine-containing compound, a
carboxyl-containing compound, a hydroxyl-containing compound and a
thiol-containing compound.
81. The conjugate of claim 80, wherein said bioactive component is
selected from the group consisting of a peptide, a protein and a
glycoprotein.
82. The conjugate of claim 81, wherein said peptide or protein or
glycoprotein is selected from the group consisting of an enzyme, a
serum protein, a serum glycoprotein, a blood cell protein, a
pigmentary protein, hemoglobin, a viral protein, a peptide hormone,
a protein hormone, a glycoprotein hormone, a hypothalamic releasing
factor, a cytokine, a growth factor and peptides and proteins and
glycoproteins that mimic or function as antagonists of any of the
foregoing group.
83. The conjugate of claim 82, wherein said serum protein is
selected from the group consisting of an albumin, an
immunoglobulin, a blood-clotting factor and peptides and proteins
and glycoproteins that mimic or function as antagonists of any of
the foregoing serum proteins.
84. The conjugate of claim 82, wherein said peptide hormone or
protein hormone or glycoprotein hormone is selected from the group
consisting of an antidiuretic hormone, chorionic gonadotropin,
luteinizing hormone, follicle-stimulating hormone, insulin,
prolactin, a somatomedin, growth hormone, thyroid-stimulating
hormone, a placental lactogen and peptides and proteins and
glycoproteins that mimic or function as antagonists of any of the
foregoing hormones.
85. The conjugate of claim 82, wherein said growth factor is
selected from the group consisting of a colony-stimulating factor,
an epidermal growth factor, a fibroblast growth factor, an
insulin-like growth factor, a transforming growth factor, a
platelet-derived growth factor, a nerve growth factor, a hepatocyte
growth factor, a neurotrophic factor, a ciliary neurotrophic
factor, a brain-derived neurotrophic factor, a glial-derived
neurotrophic factor or a bone morphogenic peptide and peptides and
proteins and glycoproteins that mimic or function as antagonists of
any of the foregoing growth factors.
86. The conjugate of claim 82, wherein said cytokine is selected
from the group consisting of erythropoietin, a lymphokine, an
interleukin, an interferon, a tumor necrosis factor, a leukemia
inhibitory factor and thrombopoietin, and peptides and proteins and
glycoproteins that mimic or function as antagonists of any of the
foregoing cytokines.
87. The conjugate of claim 82, wherein said enzyme is selected from
the group consisting of a carbohydrate-specific enzyme, a
proteolytic enzyme, an oxidoreductase, a transferase, a hydrolase,
a lyase, an isomerase and a ligase.
88. The conjugate of claim 87, wherein said oxidoreductase enzyme
is a uricase.
89. The conjugate of claim 87, wherein said proteolytic enzyme is a
plasminogen activator.
90. The conjugate of claim 1, wherein said peptide, protein or
glycoprotein is an allergen.
91. The conjugate of claim 59, wherein the bioactive compound is a
taxane or a derivative thereof.
92. The conjugate of claim 59, wherein said bioactive compound is
an antibiotic or a derivative thereof.
93. A pharmaceutical composition comprising the conjugate of claim
59 and a pharmaceutically acceptable excipient or carrier.
94. A kit comprising the conjugate of claim 1.
95. A kit comprising the pharmaceutical composition of claim
38.
96. A kit comprising the conjugate of claim 59.
97. A PEG-liposome composition, wherein the PEG component does not
comprise an alkoxyl group at any terminus and each molecule of PEG
is attached to a single lipid molecule at a single site on the
lipid molecule and on said molecule of PEG.
98. The composition of claim 97, wherein said site of attachment is
the amino group of a phosphatidyl ethanolamine.
99. The composition of claim 97, wherein said site of attachment is
the hydroxyl group of a diacylglycerol.
100. The composition of claim 97, wherein said composition is
reduced or substantially reduced in immunoreactivity compared to a
PEG-liposome composition comprising at least one alkoxyPEG or a PEG
that is attached to a lipid at more than one site or to more than
one lipid molecule.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of U.S.
application Ser. No. 10/317,092 filed Dec. 12, 2002, which claims
the benefit of the filing date of U.S. Provisional Application No.
60/414,424, filed Sep. 30, 2002. The disclosures of the
above-referenced applications are incorporated herein by reference
in their entireties.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention is in the fields of protein
biochemistry and the pharmaceutical and medical sciences. In
particular, the invention provides methods for the production of
conjugates between water-soluble polymers (e.g., poly(ethylene
glycol) and derivatives thereof) and bioactive components, which
conjugates have reduced antigenicity and immunogenicity compared to
standard polymer-bioactive component conjugates. The invention also
provides conjugates produced by such methods, compositions
comprising such conjugates, kits comprising such conjugates and
compositions and methods of use of the conjugates and compositions
in preventing, diagnosing and treating a variety of medical and
veterinary conditions.
[0004] 2. Related Art
[0005] Two key factors have hindered the development of recombinant
proteins as therapeutic agents--their generally short half-lives in
the circulation and their potential antigenicity and
immunogenicity. As used herein and generally in the art, the term
"antigenicity" refers to the ability of a molecule to bind to
preexisting antibodies, while the term "immunogenicity" refers to
the ability to evoke an immune response in vivo, whether that
response involves the formation of antibodies (a "humoral
response") or the stimulation of cellular immune responses. For the
administration of recombinant therapeutic proteins, intravenous
(i.v.) administration is often desirable in order to achieve the
highest circulating activities and to minimize problems of
bioavailability and degradation. However, the half-lives of small
proteins following i.v. administration are usually extremely short
(see examples in Mordenti, J., et al., (1991) Pharm Res
8:1351-1359; Kuwabara, T., et al., (1995) Pharm Res 12:1466-1469).
Healthy kidneys generally retain in the bloodstream proteins with
hydrodynamic radii exceeding that of serum albumin, which has a
Stokes radius of c. 36 .ANG. and a molecular weight of c. 66,000
Daltons (66 kDa). However, smaller proteins, such as granulocyte
colony-stimulating factor ("G-CSF") and ribonuclease, are cleared
rapidly from the bloodstream by glomerular filtration (Brenner, B.
M., et al. (1978) Am Physiol 234:F455-F460; Venkatachalam, M. A.,
et al. (1978) Circ Res 43:337-347; Wilson, G., (1979) J Gen Physiol
74:495-509). As a result, maintenance of therapeutically useful
concentrations of small recombinant proteins in the circulation is
problematic following i.v. administration. Therefore, higher
concentrations of such proteins and more frequent injections must
be administered. The high dose rate increases the cost of therapy,
decreases the likelihood of patient compliance and increases the
risk of adverse events, e.g., immune reactions. Both cellular and
humoral immune responses can reduce the circulating concentrations
of injected recombinant proteins to an extent that may preclude the
administration of an effective dose or may lead to
treatment-limiting events such as anaphylaxis (Pui, C.-H., et al.
(2001) J Clin Oncol 19:697-704).
[0006] Alternative routes of administration, such as subcutaneous
(s.c.) or intramuscular (i.m.) injections, can overcome some of
these problems, by providing more gradual release of recombinant
proteins into the circulation. However, the bioavailability can be
quite low, making it difficult to achieve effective circulating
concentrations of such drugs. A further problem that may be related
to the poor bioavailability of drugs administered s.c. or i.m. is
the increased probability of degradation of the therapeutic protein
at the site of injection.
[0007] Modification of recombinant proteins by the covalent
attachment of derivatives of poly(ethylene glycol) ("PEG") has been
investigated extensively as a means of addressing the shortcomings
discussed above (reviewed in Sherman, M. R., et al. (1997) in:
Poly(ethylene glycol): Chemistry and Biological Applications,
Harris, J. M., et al., eds., American Chemical Society, Washington,
D.C., pp. 155-169; Roberts, M. J., et al. (2002) Adv Drug Deliv Res
54:459-476). The attachment of PEG derivatives to proteins has been
shown to stabilize the proteins, improve their bioavailability
and/or reduce their immunogenicity in vivo. (The covalent
attachment of PEG derivatives to a protein or other substrate is
referred to herein, and is known in the art, as "PEGylation.") In
addition, PEGylation can increase the hydrodynamic radius of
proteins significantly. When a small protein, such as a cytokine or
polypeptide hormone, is coupled to a single long strand of PEG
(e.g., having a molecular weight of at least about 18 kDa), the
resultant conjugate has a larger hydrodynamic radius than that of
serum albumin and its clearance via the renal glomeruli is
dramatically retarded. The combined effects of PEGylation--reduced
proteolysis, reduced immune recognition and reduced rates of renal
clearance--confer substantial advantages on PEGylated proteins as
therapeutic agents.
[0008] Since the 1970s, attempts have been made to use the covalent
attachment of polymers to improve the safety and efficacy of
various proteins for pharmaceutical use (see, e.g., U.S. Pat. No.
4,179,337). Some examples include the coupling of PEG or
poly(ethylene oxide) (PEO) to adenosine deaminase (EC 3.5.4.4) for
use in the treatment of severe combined immunodeficiency disease
(Davis, S., et al. (1981) Clin Exp Immunol 46:649-652; Hershfield,
M. S., et al. (1987) N Engl J Med 316:589-596). Other examples
include the coupling of PEG to superoxide dismutase (EC 1.15.1.1)
for the treatment of inflammatory conditions (Saifer, M., et al.,
U.S. Pat. Nos. 5,006,333 and 5,080,891) and to urate oxidase (EC
1.7.3.3) for the elimination of excess uric acid from the blood and
urine (Inada, Y., Japanese Patent Application 55-099189; Kelly, S.
J., et al. (2001) J Am Soc Nephrol 12:1001-1009; Williams, L. D.,
et al., PCT publication WO 00/07629 A3, corresponding to U.S. Pat.
No. 6,576,235; Sherman, M. R., et al., PCT publication WO 01/59078
A2).
[0009] PEOs and PEGs are polymers composed of covalently linked
ethylene oxide units. These polymers have the following general
structure:
R.sub.1--(OCH.sub.2CH.sub.2).sub.n--R.sub.2
where R.sub.2 may be a hydroxyl group (or a reactive derivative
thereof) and R.sub.1 may be hydrogen, as in "PEG diol", a methyl
group, as in monomethoxyPEG ("mPEG"), or another lower alkyl group,
e.g., as in iso-propoxyPEG or t-butoxyPEG. The parameter n in the
general structure of PEG indicates the number of ethylene oxide
units in the polymer and is referred to herein and in the art as
the "degree of polymerization." PEGs and PEOs can be linear,
branched (Fuke, 1., et al. (1994) J Control Release 30:27-34) or
star-shaped (Merrill, E. W. (1993) J Biomater Sci Polym Ed 5:1-11).
PEGs and PEOs are amphipathic, i.e. they are soluble in water and
in certain organic solvents and they can adhere to lipid-containing
materials, including enveloped viruses and the membranes of animal
and bacterial cells. Certain random or block or alternating
copolymers of ethylene oxide (OCH.sub.2CH.sub.2) and propylene
oxide, which has the following structure:
##STR00001##
have properties that are sufficiently similar to those of PEG that
these copolymers are thought to be suitable replacements for PEG in
certain applications (see, e.g., U.S. Pat. Nos. 4,609,546 and
5,283,317). The term "polyalkylene oxides" and the abbreviation
"PAOs" are used herein to refer to such copolymers, as well as to
PEG or PEO and poly(oxyethylene-oxymethylene) copolymers (U.S. Pat.
No. 5,476,653). As used herein, the term "polyalkylene glycols" and
the abbreviation "PAGs" are used to refer generically to polymers
suitable for use in the conjugates of the invention, particularly
PEGs, more particularly PEGs containing a single reactive group
("monofunctionally activated PEGs").
[0010] Commonly, several (e.g., 5 to 10) strands of one or more
PAGs, e.g., one or more mPEGs with a molecular weight of about 5
kDa to about 10 kDa, are coupled to the target protein via primary
amino groups (the epsilon amino groups of lysine residues and the
alpha amino group of the N-terminal amino acid). More recently,
conjugates have been synthesized containing a single strand of mPEG
of higher molecular weight, e.g., 12 kDa, 20 kDa or 30 kDa. Direct
correlations have been demonstrated between the plasma half-lives
of the conjugates and an increasing molecular weight and/or
increasing number of strands of PEG coupled (Clark, R., et al.
(1996) J Biol Chem 271:21969-21977). On the other hand, as the
number of strands of PEG is increased, so is the probability that
an amino group in an essential region of the bioactive component
(particularly if the bioactive component is a protein) will be
modified, impairing its biological function (e.g., catalysis by an
enzyme or receptor binding by a cytokine). For larger proteins that
contain many amino groups, and for enzymes with substrates of low
molecular weight, this tradeoff between increased duration of
action and decreased specific activity may be acceptable, since it
produces a net increase in the biological activity of the
PEG-containing conjugates in vivo. For smaller proteins, such as
polypeptide hormones and cytokines, however, a relatively high
degree of substitution is likely to decrease the functional
activity to the point of negating the advantage of an extended
half-life in the bloodstream (Clark, R., et al., supra).
[0011] Certain of the present inventors have pioneered a variety of
PEGylation strategies and have applied them to several proteins to
achieve the desirable combination of favorable pharmacokinetics and
increased potency in vivo. These proteins include
granulocyte-macrophage colony-stimulating factor ("GM-CSF")
(Saifer, M. G. P., et al. (1997) Polym Preprints 38:576-577;
Sherman, M. R., et al. (1997) supra) and recombinant mammalian
uricase (see PCT publications WO 00/07629 and WO 01/59078; Kelly,
S. J., et al., supra; U.S. Pat. No. 6,576,235). Using GM-CSF as a
model cytokine, certain of the present inventors demonstrated that
the attachment of one or two strands of mPEG of high molecular
weight (about 36 kDa) was sufficient to enhance dramatically the
potency of recombinant murine GM-CSF in vivo (Saifer, M. G. P., et
al. (1997) supra; Sherman, M. R., et al. (1997) supra). Studies
have also been conducted in which recombinant mammalian urate
oxidase (uricase) was modified and explored as a potential
treatment for intractable gout (see PCT publications WO 00/07629,
corresponding to U.S. Pat. No. 6,576,235, and WO 01/59078, the
disclosures of which are entirely incorporated herein by
reference). When the PEG-uricase was used to treat
uricase-deficient mice (uox -/-) that displayed profound uric
acid-induced nephropathy, it was found to be well tolerated,
effective and substantially non-immunogenic. Treated mice exhibited
improved renal function for the duration of treatment (10 weeks)
and had substantially less uric acid-related kidney damage than
untreated uox -/- mice, as demonstrated by microscopic magnetic
resonance imaging (Kelly, S. J., et al. (2001) supra).
[0012] The covalent attachment of strands of a PAG to a polypeptide
molecule is disclosed in U.S. Pat. No. 4,179,337 to Davis, F. F.,
et al., as well as in Abuchowski, A., et al. (1981) in Enzymes as
Drugs, Holcenberg, J. S., et al., eds., John Wiley and Sons, New
York, pp. 367-383. These references disclose that enzymes and other
proteins modified with mPEGs have reduced immunogenicity and
antigenicity and have longer lifetimes in the bloodstream, compared
to the corresponding unmodified proteins. The resultant beneficial
properties of the chemically modified conjugates are very useful in
a variety of therapeutic applications.
[0013] To effect the covalent attachment of PEG or polyalkylene
oxides to a protein, at least one of the hydroxyl end groups of the
polymer must first be converted into a reactive functional group.
This process is frequently referred to as "activation" and the
product is called "activated PEG" or activated polyalkylene oxide.
MonomethoxyPEG that is capped on one end with an unreactive,
chemically stable methyl ether (the "methoxyl group") and on the
other end with a functional group reactive towards amino groups on
a protein molecule is most commonly used for such approaches.
So-called "branched" mPEGs, which contain two or more methoxyl
groups distal from a single activated functional group, are used
less commonly. An example is di-mPEG-lysine, in which the carboxyl
group of lysine is most often activated by esterification with
N-hydroxysuccinimide (Harris, J. M., et al., U.S. Pat. No.
5,932,462).
[0014] The activated polymers are reacted with a therapeutic agent
having nucleophilic functional groups that serve as attachment
sites. One nucleophilic functional group commonly used as an
attachment site is the epsilon amino group of lysine residues. Free
carboxylic acid groups, suitably activated carbonyl groups,
oxidized carbohydrate moieties and thiol groups have also been used
as attachment sites.
[0015] The hydroxyl group of mPEG has been activated with cyanuric
chloride and the resulting compound then coupled with proteins
(Abuchowski, A., et al. (1977) J Biol Chem 252:3582-3586;
Abuchowski, A., et al. (1981) supra). The use of this method has
disadvantages however, such as the toxicity of cyanuric chloride
and its non-specific reactivity for proteins having functional
groups other than amines, such as solvent-accessible cysteine or
tyrosine residues that may be essential for function.
[0016] In order to overcome these and other disadvantages,
alternative activated PEGs have been introduced, such as
succinimidyl succinate derivatives of mPEG ("SS-PEG") (Abuchowski,
A., et al. (1984) Cancer Biochem Biophys 7:175-186). Under mild
conditions, SS-PEG reacts quickly with proteins (within 30
minutes), yielding active, yet extensively modified conjugates.
[0017] M. Saifer, et al., in U.S. Pat. No. 5,468,478, disclose
polyalkylene glycol-mono-N-succinimidyl carbonates and conjugates
produced therefrom. S. Zalipsky, in U.S. Pat. No. 5,612,460,
discloses methods for preparation of poly(ethylene
glycol)-N-succinimidyl carbonates. This form of the polymer
("SC-PEG") reacts readily with the amino groups of proteins, as
well as peptides of low molecular weight and other materials that
contain free amino groups, with which it forms urethane bonds.
[0018] Urethane (or carbamate) linkages between the amino groups of
the protein and the PEG are also known in the art to be produced
from other PEG-carbonate derivatives (Beauchamp, C., et al. (1983)
Anal Biochem 131:25-33; Veronese, F. M., et al. (1985) Appl Biochem
Biotechnol 11:141-152). Reactive mPEG intermediates and methods for
their use are also known in the art for the synthesis of PEG
conjugates of bioactive components linked via amide bonds, ester
bonds, secondary amines and thioester bonds, among others.
[0019] T. Suzuki et al. ((1984) Biochim Biophys Acta 788:248-255)
covalently coupled immunoglobulin G ("IgG") to mPEG that had been
activated by cyanuric chloride. They studied the biological and
physicochemical properties, such as antigen-binding activity and
the molecular structure, size-exclusion chromatographic behavior,
surface activity, interfacial aggregability and heat aggregability
that induced nonspecific activation of complement by the PEG-IgG
conjugates. The coupling of PEG to IgG increased the apparent
Stokes radius and the surface activity of IgG and stabilized IgG to
heating and/or the exposure to interfaces, while no structural
denaturation of IgG was observed. The suppression of nonspecific
aggregability was attributed mainly to the steric inhibition of the
association between the PEGylated IgG molecules. These results
indicated the utility of mPEG-coupled IgG as an intravenous
preparation and also suggested the utility of PEG as an additive to
stabilize unmodified IgG for intravenous use.
[0020] K. A. Sharp et al. ((1986) Anal Biochem 154:110-117)
investigated the possibility of producing biospecific affinity
ligands for separating cells in aqueous two-phase polymer systems
on the basis of cell surface antigens. Rabbit anti-human
erythrocyte IgG was reacted with cyanuric chloride-activated mPEGs
with molecular weights of approximately 0.2, 1.9 and 5 kDa at
various molar ratios of PEG to lysine groups on the protein. The
partition coefficient of the protein in a two-phase system
containing dextran and PEG increased with increasing degree of
modification and increasing molecular weight of the mPEG. There was
a concomitant loss in ability to agglutinate human
erythrocytes.
[0021] R. H. Tullis, in U.S. Pat. No. 4,904,582, discloses
oligonucleotide conjugates wherein the oligonucleotides are joined
through a linking arm to a hydrophobic moiety, which could be a
polyoxyalkylene group. The resulting conjugates are said to be more
efficient in membrane transport, so as to be capable of crossing
the membrane and effectively modulating a transcriptional system.
In this way, the compositions can be used in vitro and in vivo for
studying cellular processes, protecting mammalian hosts from
pathogens, facilitating gene therapy, and the like.
[0022] Excessive conjugation of polymers and/or conjugation
involving the active site of a therapeutic moiety where groups
associated with bioactivity are found, however, Can often result in
loss of activity and, thus, in loss of therapeutic efficacy. This
is often the case with lower molecular weight peptides that have
few attachment sites that are not associated with bioactivity. For
example, I. Benhar et al. ((1994) Bioconjug Chem 5:321-326)
observed that PEGylation of a recombinant single-chain immunotoxin
resulted in the loss of specific target immunoreactivity of the
immunotoxin. The loss of activity of the immunotoxin was the result
of attachment of PEG to two lysine residues within the
antigen-combining region of the immunotoxin.
[0023] Although the covalent attachment of PAGs and PAOs (e.g.,
PEGs, PEOs, etc.) to therapeutic proteins is intended to eliminate
their immunoreactivity, PEGylated proteins remain weakly
immunogenic. This immunogenicity appears to be due, at least in
part, to the fact that PEG and PAO polymers are themselves somewhat
antigenic and immunogenic. For example, rabbits have been immunized
to various PEGs by injecting the animals with conjugates in which
PEG was coupled to an immunogenic carrier protein (Richter, A. W,
et al. (1983) Int Arch Allergy Appl Immunol 70:124-131). In
addition, a monoclonal antibody that reacts with the polyether
backbone of PEG has been developed by injecting mice with an mPEG
conjugate of .beta.-glucuronidase and selecting a hybridoma clone
that secretes an anti-PEG antibody (Cheng, T.-L., et al. (1999),
Bioconjug. Chem. 10:520-528; Cheng, T.-L., et al. (2000),
Bioconjug. Chem. 11:258-266; Tsai, N.-M., et al. (2001),
Biotechniques 30:396-402; Roffler, S., et al., U.S. Pat. Nos.
6,596,849 and 6,617,118; the disclosures of all of which are
incorporated herein by reference in their entireties). Another
monoclonal antibody that reacts with the polyether backbone of PEG
has been disclosed recently by Roberts, M. J., et al., in U.S.
Patent Application No. 2003/001704 A1.
[0024] A number of investigators have disclosed the preparation of
linear or branched "non-antigenic" PEG polymers and derivatives or
conjugates thereof (see, e.g., U.S. Pat. Nos. 5,428,128; 5,621,039;
5,622,986; 5,643,575; 5,728,560; 5,730,990; 5,738,846; 5,811,076;
5,824,701; 5,840,900; 5,880,131; 5,900,402; 5,902,588; 5,919,455;
5,951,974; 5,965,119; 5,965,566; 5,969,040; 5,981,709; 6,011,042;
6,042,822; 6,113,906; 6,127,355; 6,132,713; 6,177,087, and
6,180,095; see also PCT publication WO 95/13090 and published U.S.
patent application nos. 2002/0052443, 2002/0061307 and
2002/0098192). Most of the examples in the foregoing patents and
patent applications employ polymers containing one or more strands
of mPEG, e.g., di-mPEG-lysine. To date, however, there has been no
disclosure of a mechanism for rendering the PEG in such polymers or
conjugates non-antigenic.
[0025] Thus, there exists a need for the identification of methods
of producing PAO-containing (e.g., PEG- and/or PEO-containing)
conjugates, particularly conjugates between such water-soluble
polymers and therapeutic proteins, with reduced, substantially
reduced or no detectable antigenicity. Such conjugates will have
the benefits provided by the polymer component of increased
stability and bioavailability in vivo, but will not elicit a
substantial immune response in an animal into which the conjugates
have been introduced for therapeutic or diagnostic purposes.
BRIEF SUMMARY OF THE INVENTION
[0026] The present invention addresses the needs identified above,
and provides methods for the preparation of conjugates of
water-soluble polymers (e.g., poly(ethylene glycol) and derivatives
thereof) and bioactive components, particularly therapeutic
bioactive components, such as proteins. The invention also provides
polymers and conjugates produced by such methods, which polymers
and conjugates have reduced antigenicity and immunogenicity,
compared to alkoxyl-containing polymers and conjugates of the same
bioactive component prepared with alkoxyPEGs, e.g., mPEG. The
invention also provides compositions comprising such conjugates,
kits containing such conjugates and compositions and methods of use
of the conjugates and compositions in a variety of therapeutic and
diagnostic regimens.
[0027] In one aspect, the invention provides a conjugate comprising
one or more bioactive components covalently linked to at least one
linear or branched monofunctionally activated polyalkylene glycol,
wherein the mono-functionally activated polyalkylene glycol does
not comprise a methoxyl group, another alkoxyl group or an aryloxyl
group at any terminus. In certain such embodiments, the conjugate
has reduced or substantially reduced antigenicity compared to a
conjugate prepared using an alkoxypoly(ethylene glycol), e.g.,
mPEG, or a branched polymer containing mPEG, such as
di-mPEG-lysine.
[0028] Polyalkylene glycols that are particularly suitable for use
in the synthesis of the conjugates of the invention include, but
are not limited to, poly(ethylene glycols) and copolymers of
ethylene oxide and propylene oxide; particularly preferred are
PEGs, and more particularly preferred are monofunctionally
activated PEGs (e.g., PEGs that are activated at a single terminus,
including hydroxyPEG-monoaldehydes, hydroxyPEG-monovinyl-sulfones,
reactive esters of hydroxyPEG-monocarboxylic acids and
hydroxyPEG-monophenyl carbonate derivatives). Other intermediates
that can be useful for the synthesis of the reactive polymer
derivatives include other hydroxyPEG-monoacids and
hydroxyPEG-monoacetals.
[0029] In certain such embodiments, the polyalkylene glycol has a
molecular weight of from about 1,000 Daltons to about 100 kDa,
preferably about 2 kDa to about 60 kDa; about 2 kDa to about 30
kDa, about 5 kDa to about 20 kDa; about 10 kDa to about 30 kDa;
about 10 kDa to about 20 kDa; two branches each with a molecular
weight of about 2 kDa to about 30 kDa; and more preferably two
branches, each of about 18 kDa to about 22 kDa. Conjugates
according to this aspect of the invention may comprise one or more
strands of polyalkylene glycol, in certain embodiments preferably
from about one to about 10 strands, from about one to about five
strands, more preferably from about one to about three strands, and
most preferably from about one to about two strands; in other
embodiments preferably from about five to about 100 strands, from
about 10 to about 50 strands and more preferably from about six to
about 20 strands per subunit of high molecular weight enzyme
proteins. In a particularly preferred such embodiment, the
polyalkylene glycol used in the conjugate comprises one or two
strands of a monofunctionally activated poly(ethylene glycol)
(e.g., a reactive ester of a hydroxyPEG-monoacid, a
hydroxyPEG-monoaldehyde, a hydroxyPEG-monovinylsulfone or a
hydroxyPEG-monophenyl carbonate derivative) having a molecular
weight of from about 18 kDa to about 22 kDa or about 27 kDa to
about 33 kDa.
[0030] Suitable bioactive components for use in the conjugates or
compositions of the invention include, but are not limited to, a
variety of peptides, proteins, glycoproteins, organic compounds,
amine-containing compounds, carboxyl-containing compounds,
hydroxyl-containing compounds and thiol-containing compounds.
[0031] The invention also provides methods of producing conjugates
between a bioactive compound and a monofunctionally activated
polyalkylene glycol, for example comprising: (a) obtaining or
preparing a linear or branched polyalkylene glycol comprising at
least one unreactive blocking group that can be subsequently
removed, such as one or more triphenylmethyl groups ("trityl
groups"); (b) producing a derivative of the polyalkylene glycol by
reacting it with at least one derivatizing compound under
conditions such that the polyalkylene glycol is derivatized with
one derivatizing group (such as one carboxyl group) at an end that
lacks the blocking group(s); (c) removing the blocking group(s)
without removing the derivatizing group to produce, in one or more
steps, a monofunctionally activated polyalkylene glycol; and (d)
contacting the monofunctionally activated polyalkylene glycol with
at least one bioactive component under conditions that favor the
covalent binding of the bioactive component to the monofunctionally
activated polyalkylene glycol. Preferably, the conjugates produced
by such methods are of reduced, substantially reduced or
undetectable antigenicity and immunogenicity, when compared to
conjugates derivatized to the same extent with mPEG of similar
size, structure and linkage to the bioactive agent. The invention
also provides conjugates produced by such methods.
[0032] The invention also provides pharmaceutical or veterinary
compositions comprising the conjugates of the invention and at
least one excipient or carrier that is acceptable for
pharmaceutical or veterinary use.
[0033] In additional embodiments, the invention also provides
methods of preventing, diagnosing or treating physical disorders in
animals (such as mammals, including humans) using the conjugates or
compositions of the invention. One such method comprises, for
example, administering to an animal suffering from or predisposed
to a physical disorder (such as anemia, arthritis, cancers,
Alzheimer's disease, enzymatic deficiencies, cardiovascular
disease, hypertension, infectious diseases, metabolic diseases,
neurologic diseases, neutropenia, hyperuricemia and manifestations
thereof (e.g., gout), genetic deficiency diseases or disorders, and
the like) an effective amount of one or more of the conjugates or
compositions of the invention, which may be administered to the
animal, especially mammals and most especially humans, orally,
topically or parenterally, for example intravenously,
intramuscularly or subcutaneously.
[0034] In additional embodiments, the invention provides
compositions comprising one or more of the conjugates of reduced
antigenicity of the invention that may further comprise one or more
additional components or reagents, such as one or more buffer
salts, one or more carbohydrate excipients, one or more carrier
proteins, one or more enzymes, one or more detergents, one or more
nucleic acid molecules, one or more polymers such as PEG, and the
like. The invention also provides kits comprising the conjugates of
reduced antigenicity and/or compositions of the invention.
[0035] In additional embodiments, the invention provides
PEG-liposomes of reduced immunoreactivity prepared using
monofunctionally activated poly-alkylene glycols that lack methoxyl
or other alkoxyl groups, rather than monofunctionally activated
mPEG. Other preferred embodiments of the present invention will be
apparent to one of ordinary skill in light of the following
drawings and description of the invention, and of the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0036] FIG. 1 displays the results from a competitive enzyme-linked
immunosorbent assay ("ELISA") analysis. In this assay, an mPEG
conjugate of one protein was bound to the 96-well assay plate, and
the inhibition of binding of rabbit antibodies to an mPEG conjugate
of another protein by solutions of mPEG or t-butoxyPEG was
measured.
[0037] FIG. 2a displays the results from a competitive ELISA,
performed as described for FIG. 1, using PEGs of various sizes and
structures containing either one or two methoxyl groups. The
results for antibody binding are graphed as a function of the molar
concentration of methoxyl groups in each sample.
[0038] FIG. 2b displays the same data as FIG. 2a, graphed as a
function of the weight concentration of PEG (microgram/mL) instead
of the molar concentration of methoxyl groups.
[0039] FIG. 3 displays some of the data from FIGS. 1, 2a and 2b in
a format that demonstrates the direct dependence of antigenicity on
the number of methoxyl groups per molecule of PEG. These samples
include 10-kDa PEGs, one of which lacks a methoxyl group
(t-butoxyPEG), one that contains one methoxyl group (mPEG) and one
that contains two methoxyl groups [Di-(5-kDa) mPEG-lysine].
[0040] FIG. 4 illustrates a competitive ELISA, as described for
FIG. 1, in which 4.8-kDa mPEG is compared with three PEGs of the
invention that have no methoxyl groups at the ends of the linear
polymer (labeled "PharmaPEG"). The shift between the curves on the
horizontal axis indicates that the antigenicities of all three of
the PEGs of the invention are approximately 100-fold lower than
that of mPEG, when assayed with anti-mPEG antibodies.
[0041] FIG. 5a displays the results of studies in which samples of
an isomer of carbonic anhydrase ("CA II") and the same carbonic
anhydrase coupled to an average of 3-4 strands of 5-kDa mPEG were
analyzed by polyacrylamide gel electrophoresis in the presence of
sodium dodecyl sulfate ("SDS-PAGE"). Lanes 1 and 2 of the gel show
the results obtained by staining for protein using SYPRO.RTM. brand
Ruby stain and photography in a dark hood with illumination at 302
nm. Lanes 3 and 4 show the results of a Western blot of the mPEG
conjugates and the unPEGylated enzyme, respectively, in which
polyclonal rabbit anti-mPEG antibodies were used as the primary
antibodies. Lane 5 shows the positions of pre-stained protein
standards.
[0042] FIG. 5b shows the quantitation of the band intensities in
the gel and the Western blot shown in FIG. 5a, obtained with Kodak
camera and digital imaging software. The horizontal axis represents
the migration distance relative to the dye front and the vertical
axis represents the relative intensities of the protein stain or
anti-mPEG stain. The bottom tracing shows bands of pre-stained
standard proteins with apparent molecular weights, from left to
right, of 203.8, 110.9, 68.8, 51.5, 40.2, 28.9, 20.7 and 14.9 kDa.
The second tracing from the bottom is an anti-mPEG antibody stain
of PEGylated carbonic anhydrase. The third tracing from the bottom
represents the protein-stained band of carbonic anhydrase and the
top tracing represents the protein-stained bands of the mPEG
conjugates of carbonic anhydrase.
[0043] FIGS. 6a and 6b show the results of ELISA analyses of sera
from groups of three rabbits that were immunized with conjugates of
porcine uricase containing an average of about two strands of
either mPEG or hydroxyPEG ("PharmaPEG") per uricase subunit.
Antibodies against uricase were measured using assay plates coated
with porcine uricase. Antibodies against PEG were measured using
plates coated with conjugates of an unrelated protein coupled to
mPEG. FIG. 6a shows data from the second bleeding of rabbits that
had received four injections of PEG-uricase in incomplete Freund's
adjuvant. FIG. 6b shows data from the third bleeding of the same
rabbits after they had received five injections of PEG-uricase in
incomplete Freund's adjuvant.
DETAILED DESCRIPTION OF THE INVENTION
[0044] Unless defined otherwise, all technical and scientific terms
used herein have the same meanings as commonly understood by one of
ordinary skill in the art to which this invention belongs. Although
any methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
invention, the preferred methods and materials are described
hereinafter.
Definitions
[0045] About: As used herein when referring to any numerical value,
the term "about" means a value of .+-.10% of the stated value
(e.g., "about 50.degree. C." encompasses a range of temperatures
from 45.degree. C. to 55.degree. C., inclusive; similarly, "about
100 mM" encompasses a range of concentrations from 90 mM to 110 mM
inclusive).
[0046] Bioactive Component: As used herein, the term "bioactive
component" refers to a compound, molecule, moiety or complex that
has a particular biological activity in vivo, in vitro or ex vivo
upon a cell, tissue, organ or organism, and that is capable of
being bound to one or more polyalkylene glycols to form the
conjugates of the invention. Preferred bioactive components are
described in detail below.
[0047] Bound: As used herein, the term "bound" refers to binding or
attachment that may be covalent, e.g., by chemically coupling, or
non-covalent, e.g., ionic interactions, hydrophobic interactions,
hydrogen bonds, etc. Covalent bonds can be, for example, ester,
ether, phosphoester, thioester, thioether, urethane, amide,
peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and
the like. The term "bound" is broader than and includes terms such
as "coupled," "linked" and "attached."
[0048] Coupled: The term "coupled", as used herein, refers to
attachment by covalent bonds or by strong non-covalent
interactions, typically and preferably to attachment by covalent
bonds. Any method normally used by those skilled in the art for the
coupling of biologically active materials can be used in the
present invention.
[0049] Disease, disorder, condition: As used herein, the terms
"disease" or "disorder" refer to any adverse condition of a human
or animal including tumors, cancers, allergies, addiction,
autoimmunity, poisoning or impairment of optimal mental or bodily
function. "Conditions" as used herein includes diseases and
disorders but also refers to physiologic states. For example,
fertility is a physiologic state but not a disease or disorder.
Compositions of the invention suitable for preventing pregnancy by
decreasing fertility would therefore be described as a treatment of
a condition (fertility), but not a treatment of a disorder or
disease. Other conditions are understood by those of ordinary skill
in the art.
[0050] Effective Amount: As used herein, the term "effective
amount" refers to an amount of a given conjugate or composition
that is necessary or sufficient to realize a desired biologic
effect. An effective amount of a given conjugate or composition of
the present invention would be the amount that achieves this
selected result, and such an amount could be determined as a matter
of routine by a person skilled in the art. For example, an
effective amount for treating an immune system deficiency could be
that amount necessary to cause activation of the immune system,
resulting in the development of an antigen-specific immune response
upon exposure to an antigen. The term is also synonymous with
"sufficient amount." The effective amount for any particular
application can vary depending on such factors as the disease or
condition being treated, the particular composition being
administered, the size of the subject, and/or the severity of the
disease or condition. One of ordinary skill in the art can
determine empirically the effective amount of a particular
conjugate or composition of the present invention without
necessitating undue experimentation.
[0051] Immune response: As used herein, the term "immune response"
refers to a humoral immune response (i.e., the formation of
antibodies) and/or a cellular immune response leading to the
activation or proliferation of B- and/or T-lymphocytes and/or
antigen-presenting cells. In some instances, however, the immune
responses may be of low intensity and become detectable only when
using at least one substance in accordance with the invention.
"Immunogenic" refers to an agent that is capable of stimulating the
immune system of a living organism, so that one or more functions
of the immune system are increased and directed towards the
immunogenic agent.
[0052] One, a, or an: When the terms "one," "a," or "an" are used
in this disclosure, they mean "at least one" or "one or more,"
unless otherwise indicated.
[0053] Polypeptide: As used herein, the term "polypeptide" refers
to a molecule composed of monomers (amino acids) linearly linked by
amide bonds (also known as peptide bonds). It indicates a molecular
chain of amino acids and does not refer to a specific length of the
product. Thus, dipeptides, tripeptides, oligopeptides, peptides of
unspecified length and proteins are included within the definition
of polypeptide. This term is also intended to refer to the products
of post-expression modifications of the polypeptide, for example,
glycosylation, acetylation, phosphorylation and the like. A
polypeptide may be recombinant or derived from a natural biological
source, but is not necessarily translated from a designated nucleic
acid sequence. It may be generated in any manner, including by
chemical synthesis.
[0054] Protein and glycoprotein: As used herein, the term protein
refers to a polypeptide generally of a size of above about 5 or
more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more,
100 or more, 200 or more, 500 or more, 1,000 or more or 2,000 or
more amino acids. Proteins generally have a defined
three-dimensional structure, although they do not necessarily need
to, and are often referred to as folded, as opposed to peptides and
polypeptides, which often do not possess a defined
three-dimensional structure, but rather can adopt a large number of
different conformations, and are referred to as unfolded. Peptides
may, however, also have a defined three-dimensional structure. As
used herein, the term glycoprotein refers to a protein containing
at least one sugar moiety attached to the protein via an
oxygen-containing or a nitrogen-containing side chain of an amino
acid, e.g., serine or asparagine.
[0055] Purified: As used herein, when the term "purified" is used
in reference to a molecule, it means that the concentration of the
molecule being purified has been increased relative to molecules
associated with it in its natural environment, or the environment
in which it was produced, found or synthesized. Naturally
associated molecules include proteins, nucleic acids, lipids and
sugars, but generally do not include water, buffers, and reagents
added to maintain the integrity or facilitate the purification of
the molecule being purified. For example, even if a given protein
in a crude extract is diluted with an aqueous solvent during column
chromatography, protein molecules are considered to be purified by
this chromatography if naturally associated nucleic acids,
non-desired proteins and other biological molecules are separated
from the subject protein molecules. According to this definition, a
substance may be 5% or more, 10% or more, 20% or more, 30% or more,
40% or more, 50% or more, 60% or more, 70% or more, 80% or more,
90% or more, 95% or more, 98% or more, 99% or more, or 100% pure
when considered relative to its contaminants.
[0056] Residue: As used herein, the term "residue" refers to a
specific amino acid, usually dehydrated as a result of its
involvement in one or more peptide bonds, in a polypeptide backbone
or side chain.
[0057] Treatment: As used herein, the terms "treatment," "treat,"
"treated" or "treating" refer to prophylaxis and/or therapy. When
used with respect to an infectious disease, for example, the term
may refer to a prophylactic treatment that increases the resistance
of a subject to infection with a pathogen or, in other words,
decreases the likelihood that the subject will become infected with
the pathogen or will show signs of illness attributable to the
infection, as well as a treatment after the subject has become
infected in order to fight the infection, e.g., to reduce or
eliminate the infection or to prevent it from becoming worse.
Overview
[0058] A number of previous investigators have disclosed the
preparation of linear or branched non-antigenic PEG polymers or
conjugates thereof (see, e.g., U.S. Pat. Nos. 5,428,128; 5,621,039;
5,622,986; 5,643,575; 5,728,560; 5,730,990; 5,738,846; 5,811,076;
5,824,701; 5,840,900; 5,880,131; 5,900,402; 5,902,588; 5,919,455;
5,951,974; 5,965,119; 5,965,566; 5,969,040; 5,981,709; 6,011,042;
6,042,822; 6,113,906; 6,127,355; 6,132,713; 6,177,087, and
6,180,095; see also PCT publication WO 95/13090 and published U.S.
patent application nos. 2002/0052443, 2002/0061307 and
2002/0098192; the disclosures of all of which are incorporated
herein by reference in their entireties). However, the PEG and the
conjugates in these previous reports remain at least weakly
immunogenic, which can lead to the undesirable consequence of the
development of antibodies to the PEG component of the conjugates
when the conjugates are introduced into an animal for prophylactic,
diagnostic or therapeutic purposes. Such antibodies may lead to a
rapid clearing of PEG-containing bioactive conjugates, thereby
reducing the bioavailability of the therapeutic compositions
(Cheng, T.-L., et al. (1999), supra), as well as possibly inducing
an immune-complex mediated disorder. Moreover, as yet there has
been no disclosure of a mechanism for rendering the claimed PEGs or
conjugates thereof substantially non-antigenic or
non-immunogenic.
[0059] The present invention has overcome these limitations in the
art. In general, the invention provides stable compositions and
methods useful in the prevention, diagnosis and treatment of a
variety of physical disorders. More particularly, the invention
provides methods for producing reactive polymers of reduced
antigenicity and stabilized polymer conjugates of proteins,
particularly therapeutic proteins, which have reduced or
substantially reduced antigenicity or which have undetectable
antigenicity. In other embodiments, the invention provides
conjugates produced by these methods of the invention, and
compositions, particularly pharmaceutical compositions, comprising
such conjugates. In additional embodiments, the invention provides
methods of use of such conjugates and compositions in preventing,
diagnosing and treating a variety of physical disorders. The
invention also provides kits comprising one or more of the
conjugates and/or compositions of the invention.
Preparation of Conjugates of Reduced Antigenicity
[0060] In one aspect, the present invention provides methods for
preparing conjugates of reduced antigenicity, substantially reduced
antigenicity, or undetectable antigenicity, by the covalent
attachment of water-soluble polymers to one or more bioactive
compounds or components, such as one or more proteins and
particularly one or more therapeutic proteins. In such conjugates,
the polymers chosen will themselves be of reduced antigenicity,
substantially reduced antigenicity or undetectable antigenicity,
compared to standard polymers typically used for preparing
protein-polymer conjugates. As used herein, the term "reduced
antigenicity" refers to a polymer (e.g., a PAO or PAG, particularly
a PEG, and most particularly a monofunctionally activated PEG), or
a conjugate or composition comprising or synthesized using such a
polymer, wherein the ability of the polymer to react with
antibodies formed against more antigenic polymers (e.g., mPEG) has
been reduced by any amount. Preferably, the antigenicity is reduced
by at least about 30%, more preferably reduced by at least about
50%, and most preferably reduced by more than about 75% compared to
the more antigenic polymer. By extension, then, a polymer (or
conjugate or composition comprising or synthesized using such a
polymer) is said to be of "substantially reduced antigenicity" if
the polymer (or conjugate or composition) has about or less than
20%, more preferably about or less than 15%, still more preferably
about or less than 10%, and most preferably about or less than 1%,
of the antigenicity of the corresponding antigenic polymer (e.g.,
mPEG). Finally, a polymer (or conjugate or composition comprising
or synthesized using such a polymer) is said to have "no detectable
antigenicity" if the polymer, conjugate or composition has no
detectable antigenicity when assayed with art-known methods (e.g.,
ELISA or other methods of detecting antigenicity, such as those
known in the art and as described in the Examples herein).
[0061] Polymers
[0062] Polyalkylene glycols that are particularly suitable for use
in preparing the conjugates of the invention include, but are not
limited to, poly(ethylene glycols), and copolymers of ethylene
oxide and propylene oxide; particularly preferred are PEGs, and
more particularly preferred are monofunctionally activated
hydroxyPEGs (e.g., hydroxyPEGs activated at a single terminus,
including reactive esters of hydroxyPEG-monocarboxylic acids,
hydroxyPEG-monoaldehydes, hydroxyPEG-monoamines,
hydroxyPEG-monohydrazides, hydroxyPEG-monocarbazates,
hydroxyPEG-monoiodoacetamides, hydroxy-PEG-monomaleimides,
hydroxyPEG-monoorthopyridyl disulfides, hydroxy-PEG-monooximes,
hydroxyPEG-monophenyl carbonates, hydroxyPEG-monophenyl glyoxals,
hydroxyPEG-monothiazolidine-2-thiones, hydroxy-PEG-monothioesters,
hydroxyPEG-monothiols, hydroxyPEG-monotriazines and
hydroxyPEG-monovinylsulfones).
[0063] Particularly preferred polymers for use in preparing the
conjugates of the present invention, which have reduced
antigenicity, substantially reduced antigenicity, or no detectable
antigenicity, are monofunctionally activated PEGs that do not
contain methoxyl groups, other alkoxyl groups or aryloxyl groups.
The substitution of such monofunctionally activated PEGs in place
of monofunctionally activated mPEG in the synthesis of conjugates
of the invention confers on the resulting conjugates an
unexpectedly decreased antigenicity, i.e., a decreased ability to
interact with antibodies developed against mPEG conjugates of the
same bioactive component. The resultant conjugates also have
decreased immunogenicity, i.e., decreased ability to evoke an
immune response.
[0064] In one aspect of the invention, monofunctionally activated
PEGs can be synthesized by using suitable reversibly blocked
derivatives of the activating group as an initiator for
polymerization of ethylene oxide (Akiyama, Y., et al. (2000)
Bioconjug Chem, 11:947-950). Akiyama et al. provide conditions for
the synthesis of a monohydroxyl, monoacetal derivative of PEG by
using potassium 3,3-diethoxypropanolate as the initiator for
polymerization of ethylene oxide. Since Akiyama et al. did not
recognize the most desirably reduced antigenicity or immunogenicity
of this intermediate, they proceeded to convert the terminal
hydroxyl group to a thiol by terminating the polymerization by the
addition of methanesulfonyl chloride, thereby producing a
heterobifunctional PEG, instead of a PEG derivative of this
invention. As further evidence that this group of workers did not
recognize the utility of a hydroxyl terminated monofunctionally
activated PEG, they have published and patented methods for
synthesis of alternative heterobifunctional PEGs from monohydroxyl,
monofunctionally activated PEGs and in some cases have even
"end-capped" the hydroxyPEGs with methoxyl groups. Similarly,
Bentley, M. D., et al., in published U.S. Patent Application No.
2002/0072573 A1, disclose polymer compositions and methods that
reflect no recognition of the immunologic advantage of
hydroxyl-terminated monofunctionally activated polymers and teach
the desirability of converting the terminal hydroxyl groups of such
polymers to methoxyl groups.
[0065] In an alternative aspect of the present invention,
monofunctionally activated PEGs can be synthesized by controlling
the extent of activation of linear PEGs containing hydroxyl groups
at both ends ("PEG diols") in order to limit the amount of
bis-activated PEG to an acceptably low level, e.g., <5%,
preferably <2% or more preferably <1%, as an alternative to
the method shown in Example 5. In a particularly preferred aspect,
monofunctionally activated PEGs can be synthesized from
monofunctional PEGs from which an unreactive blocking group can be
removed following the derivatization of the PEG, without removing
the derivatizing group. An example of a derivatized PEG is a
PEG-carboxylic acid and examples of unreactive blocking groups that
can be removed following derivatization are aryloxyl groups
(Bentley, M. D., et al, PCT publication WO 01/26692 A1), trityl
groups (Kocienski, P. J., (1994) Protecting Groups, Georg Thieme
Verlag, Stuttgart, pp. 54-58), and t-butoxyl groups. The
t-butoxyPEG-carboxylic acid can be activated, e.g., with
N-hydroxysuccinimide. Finally, the t-butoxyl group can be removed
by anhydrous acidolysis to produce an activated PEG carboxylic acid
derivative that has a hydroxyl group, instead of a methoxyl group
at the distal end of the polymer. In a more preferred embodiment,
the t-butoxyPEG-carboxylic acid can be converted to
hydroxyPEG-carboxylic acid by acidolysis prior to activation of the
carboxyl group with N-hydroxysuccinimide. In another embodiment of
this invention, t-butoxyPEG-acetals are synthesized by contacting
t-butoxyPEG with a haloacetal and converting the product to a
hydroxyPEG-acetal or hydroxyPEG-aldehyde by selective anhydrous
acidolysis to remove the t-butoxyl group. The acetal may be
converted to an aldehyde (or an aldehyde hydrate) in preparation
for its coupling to an amine-containing compound by reductive
alkylation (Bentley, M. D., et al, U.S. Pat. No. 5,990,237). In
another embodiment, an aryloxyl protecting group that is distal
from the reactive terminus of the polymer can be removed by
catalytic hydrogenolysis, thereby producing a monoactivated
hydroxyPAG of this invention. Alternatively, reversible blocking of
all except one of the terminal hydroxyl groups, as described in
Example 6, can be employed in the synthesis of monofunctionally
activated hydroxyPAGs.
[0066] The PAG polymers used in preparing the conjugates of the
present invention may be linear polymers, or may be branched at one
or more points within the polymer molecule. In addition, the
polymers used to form the conjugates of the invention may be
homopolymers, in which multiple units of a single monomer type are
linked together to form the polymer, such as poly(ethylene glycol)
or they may be heteropolymers or copolymers (in which monomeric
units of two or more structures are linked together to form the
polymer, such as a copolymer of ethylene oxide and propylene
oxide). Such copolymers may be random copolymers, block copolymers
or alternating copolymers.
[0067] Polymers used in accordance with the invention may be
unreactive polymers or reactive polymers. As used herein,
"unreactive polymers" are those polymers that will not attach
covalently to a protein. Examples of such "unreactive polymers"
include, but are not limited to, mPEG, which is a linear polymer of
ethylene oxide units with a hydroxyl group at one end and a
methoxyl group at the other end, and PEG diol, which is a linear
polymer of ethylene oxide units with hydroxyl groups at both ends.
As used herein, "reactive polymers" are those polymers that can
react with solvent-accessible nucleophilic groups, e.g., thiol
groups or amino groups on a bioactive component (such as a
protein), including but not limited to the alpha amino group or the
epsilon amino groups of lysine residues. Examples of "reactive
polymers" include, but are not limited to, PEGs in which a hydroxyl
end group has been converted to or replaced by an electrophilic
group, such as succinimidyl propionic acid (as in "SPA-PEG") or a
p-nitrophenyl carbonate (as in "NPC-PEG"), or an aldehyde as in
PEG-aldehyde. In addition to polyalkylene oxides, suitable polymers
may include polyvinyl alcohols, polyoxyethylene-oxymethylene)
copolymers, polyamides (e.g., Rose, K., PCT publication WO
00/12587), polycarboxylates, poly(vinylpyrrolidones) (von Specht,
B.-U., et al. (1973) Hoppe-Seyler's Z Physiol Chem 354:1659-1660),
poly D-amino acids and/or poly L-amino acids,
polyacryloyl-morpholine (Rocca, M., et al. (1996) Int J Artif
Organs 19:730-734) and dextrans (Iakunitskaya, L. M., et al. (1980)
Prikl Biokhim Mikrobiol 16:232-237). Derivatives of PEGs, PEOs and
other PAOs that react more or less selectively with various sites
on the target bioactive components are well known in the art and
can be purchased from suppliers such as Fluka (Milwaukee, Wis.);
NOF Corporation (Tokyo, Japan); Shearwater Corporation (Huntsville,
Ala.), a subsidiary of Nektar Therapeutics (San Carlos, Calif.);
Sigma Chemical Company (St. Louis, Mo.) or SunBio, Inc. (Anyang
City, South Korea).
[0068] Activated forms of polymers that are suitable for use in the
methods and compositions of this invention can include any hydroxyl
terminated, monofunctionally active forms of polymers that are
known in the art. For example, linear and branched PAOs of various
sizes are suitable, including those with molecular weights
(excluding the mass of the activating group) in the range of about
1 kDa to about 100 kDa. Suitable ranges of molecular weights
include but are not limited to about 2 kDa to about 60 kDa; about 2
kDa to about 30 kDa; about 5 kDa to about 20 kDa; about 10 kDa to
about 20 kDa; and about 18 kDa to about 60 kDa, about 20 kDa or
about 30 kDa. In the case of linear PEGs, the molecular weight
range of about 20 kDa to about 30 kDa corresponds to a degree of
polymerization (n) in the range of about 450 to about 680 monomeric
units of ethylene oxide. It should be noted that the advantages of
coupling a therapeutic protein to polymers having this latter
relatively high range of molecular weights (i.e., >20-30 kDa)
were first observed long before the immunogenicity of mPEG was
recognized (Saifer, M., et al., PCT publication WO 89/01033,
published Feb. 9, 1989, which is incorporated herein by reference
in its entirety).
[0069] Optionally, a linear polymer can have a reactive group at
one end or both ends, thereby creating a "reactive polymer." In
certain embodiments of this invention, it can be desirable to use
the succinimidyl ester of the monopropionic acid derivative of PEG,
as disclosed in Harris, J. M., et al., U.S. Pat. No. 5,672,662,
which is incorporated herein fully by reference, or other
succinimide activated PEG-carboxylic acids. In certain other
embodiments, it can be desirable to use either the succinimidyl
carbonate derivatives of PEG ("SC-PEG"), as described in Saifer,
M., ci al., U.S. Pat. Nos. 5,006,333; 5,080,891; 5,283,317 and
5,468,478, or the p-nitrophenyl carbonate derivative of PEG, as
disclosed in Kelly, S. J., et al. (2001) supra; PCT publication WO
00/07629 A2, supra and corresponding U.S. Pat. No. 6,576,235, and
in PCT publication WO 01/59078 A2 supra. Moreover, other types of
reactive groups can be used to synthesize polymer conjugates of
proteins. These derivatives include, but are not limited to,
aldehyde derivatives of PEGs (Royer, G. P., U.S. Pat. No.
4,002,531; Harris, J. M., et al., U.S. Pat. No. 5,252,714), amine,
bromophenyl carbonate, carbonylimidazole, chlorophenyl carbonate,
fluorophenyl carbonate, hydrazide, carbazate, iodoacetamide,
maleimide, orthopyridyl disulfide, oxime, phenylglyoxal,
thiazolidine-2-thione, thioester, thiol, triazine and vinylsulfone
derivatives of PEGs.
[0070] In certain embodiments of the invention, it is desirable to
minimize the formation of intramolecular and intermolecular
cross-links by polymers such as PEG during the reaction in which
the polymer is coupled to the bioactive component to produce the
conjugates of the invention. This can be accomplished by using
polymers that are activated at only one end (referred to herein as
"monofunctionally activated PEGs" or "monofunctionally activated
PAGs") or polymer preparations in which the percentage of
bifunctionally activated polymers (referred to in the case of
linear PEGs as "bis-activated PEG diols") is less than 30%, or more
preferably less than 10% or most preferably less than 2% (w/w). The
use of activated polymers that are predominantly monofunctional can
minimize the formation of all of the following: intramolecular
cross links within an individual protein molecule, "dumbbell"
structures, in which one strand of polymer connects two protein
molecules, and larger aggregates or gels. When activated polymers
that react with amino groups are used, the theoretical maximum
number of strands of polymer that can be attached to one molecule
of protein corresponds to the total number of amino groups. The
actual number of amino groups that are accessible on the surface of
a protein under any particular conditions of polymer coupling may
be smaller than the theoretical maximum.
[0071] Conjugates of the invention may comprise one or more strands
of polyalkylene glycol, preferably from about one to about 100
strands, from about one to about 20 strands per subunit of
therapeutic enzymes, and from about one to about three strands, and
more preferably from about one to about two strands per subunit of
receptor-finding cytokines, growth factors, protein hormones and
colony stimulating factors. In a particularly preferred such
embodiment, the polyalkylene glycol used in preparing the conjugate
comprises one or two strands of poly(ethylene glycol) (particularly
a carboxyPEG, an hydroxyPEG, a dihydroxyPEG or a PEG-acetal). In
certain such embodiments, the linear or branched polyalkylene
glycol has a molecular weight of from about 1 kDa to about 100 kDa,
preferably about 2 kDa to about 60 kDa; about 5 kDa to about 20
kDa; about 10 kDa to about 20 kDa; about 18 kDa to about 60 kDa;
and most preferably about 18 kDa to about 22 kDa or about 27 kDa to
about 33 kDa, if linear, and a total of about 36 kDa to about 44
kDa, if the polymer has two branches of equal mass.
Bioactive Components
[0072] As noted above, the conjugates of the invention comprise one
or more PAGs or PAOs, and particularly one or more strands of PEG,
covalently attached to one or more bioactive components. Bioactive
components to which one or more polymers (or strands thereof) have
been covalently attached are referred to herein variously and
equivalently as "conjugated bioactive components" or "modified
bioactive components." These terms are to be distinguished herein
from "unconjugated bioactive components," "initial bioactive
components" or "unmodified bioactive components," all of which
terms refer to bioactive components that have not had one or more
polymers covalently attached thereto. In another aspect, the
present invention provides methods and compositions for stabilizing
solutions of bioactive components by the admixture of polymers
thereto. It is to be understood, however, that an "unconjugated,"
"unmodified" or "initial" bioactive component may contain other,
non-polymer conjugations or modifications when compared to a wild
type or native molecule, and would still be considered to be
"unconjugated," "unmodified" or "initial" in accordance with the
present invention, since the bioactive component would be
"unconjugated," "unmodified" or "initial" with respect to the
attachment of polymers.
[0073] The term "stabilizing" a bioactive component (or "methods of
stabilization" or "stabilized bioactive component") indicates that
a bioactive component has been stabilized according to the methods
of this invention (i.e., a bioactive component to which a polymer
has been covalently attached or admixed according to the methods of
the invention). Such stabilized bioactive components will exhibit
certain altered biochemical and biophysical characteristics when
compared to a bioactive component that has not been stabilized
(i.e., a bioactive component to which a polymer has not been
covalently attached or admixed). Included among such altered
biochemical and biophysical parameters, particularly for proteins
such as enzymes, may be decreased autolysis and particularly the
maintenance of the enzymatic activity of a protein during
incubation under certain harsh environmental or experimental
conditions. In certain embodiments of the invention, the altered
biochemical and biophysical parameters may include, for example, an
increased half-life in the circulation in vivo, increased
bioavailability, and the like.
[0074] Any component (typically a molecule or macromolecular
complex) having biological (i.e., physiological, biochemical or
pharmaceutical) activity can be suitably used as an initial
component in the present invention. Such bioactive components
include, but are not limited to, proteins, polypeptides, peptides,
therapeutic viruses, organic compounds, and the like. Bioactive
components also include fragments, variants and derivatives of such
proteins, polypeptides, peptides, therapeutic viruses, organic
compounds and the like, particularly such fragments, variants and
derivatives having biological (i.e., physiological, biochemical or
pharmaceutical) activity.
[0075] Suitable organic compounds useful as bioactive components in
the present invention include, without limitation, moieties such as
taxanes, anthracycline, compounds including daunorubicin,
doxorubicin, p-aminoaniline mustard, melphalan, cytosine
arabinoside ("Ara-C") and other anti-metabolic compounds, e.g.,
gemcitabine, etc. Alternatively, the bioactive component can be a
cardiovascular agent, anti-neoplastic, anti-infective, anti-fungal
such as nystatin and amphotericin B, anti-anxiety agent,
gastrointestinal agent, an agent active in the central nervous
system, analgesic, fertility agent, contraceptive agent,
anti-inflammatory agent, steroidal agent, anti-uricemic agent,
vasodilating agent, vasoconstricting agent, and the like.
[0076] Suitable peptides, polypeptides, enzymes and other proteins,
glycoproteins and the like that are useful as bioactive components
in the present invention include any peptide, polypeptide, enzyme
or other protein, etc., having at least one available amino group,
thiol group or other group to which polymers can be attached. Such
components include materials that have physiological or
pharmacological activities, as well as those that are able to
catalyze reactions in organic solvents. Peptides, polypeptides and
proteins of interest include, but are not limited to, hemoglobin,
serum proteins such as blood-clotting factors, e.g., Factors VII,
VIII, and IX, immunoglobulins, insulin, cytokines such as
interleukins, e.g., IL-1 through IL-18, interferons (e.g.,
IFN-alpha, IFN-beta, IFN-gamma and consensus IFN), colony
stimulating factors including without limitation GM-CSF, G-CSF,
macrophage colony stimulating factor, thrombopoietin, megakaryocyte
growth and development factor, erythropoietin, platelet derived
growth factor, phospholipase-activating protein ("PLAP"), leukemia
inhibitory factor ("LIF," also known in the art as "Steel Factor"),
neurotrophic factors and stem cell factor and peptide mimetics
thereof. Receptor-binding antagonists of bioactive agents are
themselves suitable for use as bioactive components of the present
invention. Other proteins of general biological or therapeutic
interest include insulin, plant proteins such as lectins and
ricins, tumor necrosis factors and related proteins, growth factors
such as transforming growth factors, e.g., TGF-alpha or TGF-beta,
fibroblast growth factors, epidermal growth factors, hepatocyte
growth factors, hormones, somatomedins, erythropoietin, pigmentary
hormones, hypothalamic releasing factors, antidiuretic hormones,
prolactin, chorionic gonadotropin, follicle-stimulating hormone,
thyroid-stimulating hormone, prolactin, tissue plasminogen
activator, receptor-binding protein antagonists thereof, and the
like. Many such proteins exist in both glycosylated and
non-glycosylated forms. The non-glycosylated forms may result from
their production using recombinant techniques in prokaryotes. Such
non-glycosylated products are among the peptides and proteins that
are suitable bioactive components of the present invention.
[0077] Enzymes of interest include carbohydrate-specific enzymes,
proteolytic enzymes, oxidoreductases, transferases, hydrolases,
lyases, isomerases and ligases. Without being limited to particular
enzymes, examples of enzymes of interest include asparaginase,
arginase, arginine deiminase, adenosine deaminase, superoxide
dismutase, endotoxinases, catalase, chymotrypsin, lipases,
uricases, adenosine diphosphatase, tyrosinases and bilirubin
oxidase. Carbohydrate-specific enzymes of interest include glucose
oxidases, glucosidases, galactosidases, glucocerebrosidases,
glucuronidases and the like.
[0078] Also suitable for use as a bioactive component in the
conjugates of the present invention is any compound demonstrating
bioactivity in vivo. Such compounds include, without limitation,
amino acid sequences, nucleic acids (DNA, RNA), peptide nucleic
acids ("PNAs"), antibody fragments, single-chain binding proteins
(see, e.g., Ladner, R. C., et al., U.S. Pat. No. 4,946,778, the
disclosure of which is incorporated herein by reference), binding
molecules including soluble receptors, polyclonal antibodies,
monoclonal antibodies, catalytic antibodies and the products of
fusion of antibodies or fragments thereof.
[0079] The proteins or portions thereof can be prepared or isolated
by using techniques known to those of ordinary skill in the art
such as chemical synthesis, cell, tissue or organ culture,
extraction from animal sources, or by recombinant DNA
methodologies. Transgenic sources of the amino acid sequences,
polypeptides and proteins and the like are also contemplated. Such
materials can be obtained from transgenic animals, e.g., mice,
rabbits, pigs, goats and cows, wherein the proteins are expressed
in milk, blood or tissues, or in the eggs of transgenic birds.
Transgenic insects and fungal or baculovirus expression systems are
also contemplated as sources. Moreover, mutant versions of proteins
are also within the scope of the invention.
[0080] Other proteins of interest are allergenic proteins such as
ragweed, Antigen E, honeybee venom, mite allergen and the like. The
foregoing are illustrative of the proteins that are suitable for
the present invention. It is to be understood that other peptides,
polypeptides or proteins, or fragments thereof, that are not
specifically mentioned herein but that have one or more available
amino groups or thiol groups suitable for coupling with one or more
polymers according to the invention, are also intended and are
within the scope of the present invention.
[0081] In a preferred aspect of the invention, the compound that is
capable of polymer coupling is a biologically active compound that
is suitable for medicinal or diagnostic use in the treatment of
animals, e.g., mammals, including humans, for conditions for which
such treatment is desired. The foregoing list is meant to be
illustrative and not limiting for the compounds that can be
modified. Those of ordinary skill will realize that other such
compounds can be similarly modified without undue experimentation.
It is to be understood that those biologically active materials not
specifically mentioned but having one or more available
nucleophilic groups such as amino groups or thiols that are
accessible for coupling with one or more polymers according to the
invention are also intended and are within the scope of the present
invention.
[0082] It is noted that bioactive components suitable for
incorporation into the conjugates of the invention may be
substances or compounds that are not active by themselves, while in
the conjugate or immediately after hydrolytic release from the
conjugate, but that can become active after undergoing a further
chemical processing or reaction. For example, an anticancer drug
that is delivered to the bloodstream in the form of a conjugate of
the present invention may remain inactive until entering a cancer
or tumor cell, whereupon it is activated by a chemical process that
occurs within the cancer or tumor cell, e.g., by an enzymatic
reaction unique to or especially effective in that cell.
[0083] Other compounds suitable for use as the bioactive compounds
in the conjugates and compositions of the invention include
hydroxyl-containing compounds, such as camptothecin and related
inhibitors of topoisomerase I. Camptothecin is a water-insoluble
cytotoxic alkaloid produced by Camptotheca accuminata trees,
indigenous to China, and by Nothapodytes foetida trees, indigenous
to India. Camptothecin and related compounds and analogs are also
known to be potential anticancer or antitumor agents and have been
shown to exhibit these activities in vitro and in vivo (see, e.g.,
U.S. Pat. Nos. 4,943,579, 5,004,758 and Re 32,518, the contents of
which are incorporated herein by reference). Such compounds and
derivatives thereof can be made using known synthetic techniques
without undue experimentation. Preferred camptothecin derivatives
for use herein include those that include a 20-OH or another
hydroxyl group that is capable of reacting directly with activated
fowls of the polymers such as the monofunctionally activated PEGs
of this invention.
[0084] Additional hydroxyl-containing moieties suitable for use as
bioactive components in the present conjugates include taxanes and
paclitaxel derivatives. For purposes of the present invention, the
term "taxane" includes all compounds within the taxane family of
terpenes. Thus, Taxol (paclitaxel), 3'-substituted
t-butoxycarbonyl-amine derivatives (taxoteres) and the like, as
well as other analogs that are readily synthesized using standard
organic techniques or are available from commercial sources such as
Sigma (St. Louis, Mo.), are within the scope of the present
invention. These compounds and their derivatives have been found to
be effective anti-cancer agents. Numerous studies indicate that the
agents have activity against a variety of malignancies and other
cancers.
[0085] As the ordinarily skilled artisan will appreciate, any
bioactive component known and readily available in the art is
suitable for conjugation with monofunctional polymers having
reduced antigenicity, substantially reduced antigenicity or
undetectable antigenicity, according to the present invention. In
accordance with certain aspects of the invention, these initial
bioactive components are used to produce conjugates in which one or
more PAGs or PAOs are covalently linked to the bioactive molecule.
Sites on the initial bioactive component molecules to which
polymers may be attached advantageously include lysine residues
found on peptide molecules, which residues each have two amino
groups. One of these amino groups (the alpha amino group)
participates in peptide bond formation (except when the lysine is
the amino-terminal residue of the protein), leaving the other amino
group (the epsilon amino group) available for polymer coupling.
Other sites on protein or peptide molecules to which polymers
advantageously may be attached include, among others, the alpha
amino group at the amino-terminal residue of the polypeptide; the
sulfhydryl groups of cysteine residues on the protein or peptide
(Braxton, S. M., U.S. Pat. No. 5,766,897), to which polymers
activated with vinyl sulfone, maleimide, iodoacetamide,
bromoacetamide or orthopyridyl disulfide, among other
thiol-reactive groups that are known in the art, can be coupled;
the guanido groups of arginine residues on the protein or peptide
(Sano, A., et al., U.S. Pat. No. 5,093,531), to which polymers
activated with phenylglyoxal can be coupled; the alpha carboxyl
group of the C-terminal residue, the beta carboxyl groups of
aspartate residues on the protein or peptide and the gamma carboxyl
groups of the glutamate residues on the protein or peptide (Sakane,
T., et al. (1997) Pharm Res 14:1085-1091), to which amino or
hydrazide derivatives of the polymer can be coupled. Of course,
other suitable sites on the protein or peptide molecule to which
one or more polyalkylene oxides may be attached advantageously will
be readily apparent to one of ordinary skill in the art,
particularly upon consideration of the primary and tertiary
structures of the peptide and the disclosures herein.
[0086] Before coupling a polymer to a target bioactive component
(e.g., a protein), it can be advantageous to purify the component
to remove contaminants; otherwise, the analysis of the extent of
modification of the intact component can be complicated by the
formation of polymer conjugates of the fragments of the component
and other contaminants. Purification of the bioactive component may
be advantageous regardless of whether the protein to be conjugated
has been obtained from natural sources or produced by recombinant
methods, since contaminants in the preparations can be expected
from either source. Purification of a given bioactive component can
be accomplished by any art-known method that will be familiar to
the ordinarily skilled artisan, including but not limited to
electrophoresis, dialysis, salt extraction (such as ammonium
sulfate precipitation), chromatography (such as affinity
chromatography, ion-exchange chromatography, size-exclusion
chromatography, high performance liquid chromatography ("HPLC"),
fast protein liquid chromatography ("FPLC") and the like) or a
combination thereof. It is to be understood, however, that
purification of a given bioactive component is not essential for
preparation of the polymer-bioactive component conjugates of the
present invention, since bioactive components (especially proteins)
in crude preparations can also be advantageously conjugated with
polymers according to the methods of the present invention.
Coupling of Polymers to Bioactive Components
[0087] The PAGs employed in the practice of the present invention,
which, as indicated above, are preferably activated by reaction
with a coupling group, can be attached to any of several groups
that may be present on the bioactive component molecule, e.g.,
carboxyl groups or amino groups that are not involved in peptide
bonds, thiol groups and phenolic hydroxyl groups. For certain
peptides or proteins, it is preferred that the activated PAGs be
coupled to the N-terminal alpha amino group and/or to the amino
groups of lysine residues and/or to the sulfhydryl groups of
cysteine residues.
[0088] The crude or purified bioactive component (e.g., protein)
can be incubated with activated polymer in a buffer having a pH in
the range of about 11 or the highest pH at which any inactivation
of the protein caused by alkalinity can be reversed, down to about
pH 5 or the lowest pH at which any inactivation of the protein
caused by acidity can be reversed (see Arakawa, T., et al. (1990)
Biopolymers 29:1065-1068). As is known in the art, and as one of
ordinary skill will readily recognize, the use of a low pH for
polymer coupling to proteins can be desirable for certain proteins
or linkage chemistries. However, the use of a higher pH can be
advantageous for certain other proteins and certain coupling
chemistries, depending on the effects of pH on the solubility and
stability of the protein and on the rate of inactivation of the
activated polymer (whether spontaneous or catalyzed by the protein
itself) relative to the rate of attachment of the polymer to the
target protein according to methods that are known in the art.
[0089] The reaction between the PAG and the bioactive component is
normally carried out in solution, preferably an aqueous buffer
solution providing a pH in the range of from about 5 to about 11.
Particularly preferred for coupling a PAG to a proteinaceous
bioactive component (e.g., a polypeptide, peptide, protein, or
fragments thereof) are pH values of from about 7 to about 9, most
preferably from about 7 to about 8. In other embodiments, pH values
of about 4.5 to about 6.5 are preferred. Examples of buffer
solutions that will provide pH values in these ranges at 25.degree.
C. include, but are not limited to: [0090] 50 mL of 0.1 molar
potassium dihydrogen phosphate+5.6 to 46.1 mL 0.1 molar NaOH,
diluted to 100 mL [0091] 50 mL of 0.025 molar borate+2.0 to 20.5 mL
0.1 molar HCl, diluted to 100 mL [0092] 50 mL of 0.025 molar
borate+0.9 to 18.3 mL 0.1 molar NaOH, diluted to 100 mL [0093] 50
mL of 0.05 molar sodium bicarbonate+5.0 to 10.7 mL 0.1 molar NaOH,
diluted to 100 mL [0094] 50 mL of 0.05 molar acetic acid+5.0 to 30
mL 0.1 molar NaOH, diluted to 100 mL [0095] 50 mL of 0.05 molar
Tris HCl+10 to 50 mL 0.1 molar Tris base, diluted to 100 mL The
precise adjustment of the quantity of acid or base to be used to
provide a particular desired pH will be readily determinable by
those skilled in the art.
[0096] If, in a given instance, the use of a biological buffer
should be required, one of the following may be employed: [0097]
Hydroxyethylpiperizine-ethane sulfonic acid ("HEPES") [0098]
3-(N-Morpholino)propane sulfonic acid ("MOPS") [0099]
3-(N-Morpholino)-2-hydroxypropane sulfonic acid ("MOPSO") [0100]
piperazine-N,N'-bis(2-hydroxypropane sulfonic acid) ("POPSO")
[0101] The reaction between the PAG and the bioactive component
will normally be performed under conditions that will not give rise
to inactivation or denaturation, e.g., at temperatures at which the
bioactive component retains substantial bioactivity and subject to
no more agitation than necessary to assure adequate mixing of the
reactants. The reaction between the PAG and bioactive proteins will
preferably be conducted at a temperature in the range of from about
4.degree. C. to about 40.degree. C. More preferably, the reaction
will be conducted at between about 4.degree. C. and 8.degree. C. or
at room temperature, i.e. from about 20.degree. C. to about
25.degree. C. The reactions between the PAG and non-protein
bioactive agents, e.g., peptides and bioactive organic chemicals,
may be carried out at higher or lower temperatures that are
compatible with the stability of the particular bioactive organic
chemical that is being coupled to the PAG.
[0102] It will be readily understood by those skilled in the art
that the amount of PAG employed relative to the amount of bioactive
component will be dependent upon the desired extent of polymer
coupling to the bioactive component. For example, when it is
desired to react a PAG with a particular fraction of the
solvent-accessible lysine residues (in cases where the bioactive
component is a polypeptide), a molar concentration of PAG at least
equal to that of the lysines to be coupled will be required.
Clearly, if fewer than all of the solvent-accessible reaction sites
on the bioactive component molecule are to be derivatized,
correspondingly less PAG will be required. In general, however,
where molar excesses of PAGs are used, the present inventors have
determined that molar excesses on the order of 2 to 10 can be
preferred.
[0103] The time required for the reaction will depend upon a number
of factors, such as reaction temperature, the concentrations of
reactants, and the extent of derivatization desired. The course of
the reaction can be monitored by conventional means, such as the
periodic analysis of samples by size-exclusion chromatography or
gel electrophoresis. The reaction can be terminated conveniently
when desired by the addition of a low molecular weight compound
having a reactive group, e.g., glycine, to scavenge excess
amine-reactive PAG or by chromatographic fractionation. At room
temperature, reaction time of about 15 minutes to about 24 hours
will typically be required to react the PAG with the binding groups
of most bioactive components (e.g., the lysine groups of
polypeptide chains). Longer reaction times may be required at lower
temperatures. The skilled practitioner will understand that the
time for conjugation, as well as the amount and type of PAG, must
not be such as to inactivate the bioactive component being
employed, i.e., must not result in substantial loss of the
biological activity of the bioactive component. By "not resulting
in substantial loss of biological activity of the bioactive
component" it is meant that the PAG-conjugated bioactive component
demonstrates at least about 10%, preferably at least about 20%,
35%, 50%, 75%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99% or more of
the level of bioactivity (e.g., enzymatic activity; receptor
binding ability; anti-neoplastic activity; etc.) that is
demonstrated in vitro or in vivo by the same bioactive component
that has not been conjugated with a PAG.
[0104] Purification of the polymer-coupled bioactive component can
be effected by means commonly employed by those skilled in the art,
such as, for example, size-exclusion chromatography, ion-exchange
chromatography, ultrafiltration, dialysis, and the like. Solutions
of the reaction product can, if desired, be concentrated with a
rotary evaporator and the product can be obtained in the dry state
by lyophilization.
[0105] Depending upon the particular bioactive component used and
the extent to which it is reacted with the PAG, the resulting
adduct is expected to be useful diagnostically or therapeutically,
exhibiting, as compared to the unreacted bioactive component,
decreased antigenicity and immunogenicity, increased circulating
life, and increased stability, while maintaining a useful level of
biological activity.
[0106] The bioactive component can be reacted with the
monofunctionally activated branched poly(ethylene glycol) polymers
discussed above (particularly one or more monofunctionally
activated, branched dihydroxyPEGs, e.g., dihydroxyPEG-lysine) in an
aqueous reaction medium that can be buffered, depending on the pH
requirements of the nucleophile and the activated polymer. The
optimal pH for the reaction is generally between about 6.5 and
about 8.5 and preferably about 7.4 for maintaining the solubility
and stability of most polypeptides. The optimal pH for coupling an
activated PAG, e.g., NPC-PEG, to a mammalian uricase is
approximately pH 10, while the optimal pH for selectively coupling
certain activated PAGs to the N-terminal alpha amino group of a
protein or peptide is in the range of about 4 to about 7. The
optimal reaction conditions necessary to maintain the stability of
the bioactive component, the reaction efficiency, etc., are within
the level of ordinary skill in the art. The preferred temperature
range is between about 4.degree. C. and about 40.degree. C. The
reaction temperature must not exceed the temperature at which the
nucleophile may denature or decompose. It is preferred that the
nucleophile be reacted with an excess of the activated branched
polymer. Following the reaction, the conjugate is recovered and
purified, for example, by diafiltration, column chromatography,
combinations thereof, or the like.
[0107] The use of molecular modeling can facilitate a strategy for
the optimization of polymer coupling to a protein. For example,
X-ray crystallo-graphic data can be used to generate computerized
images of the solvent-accessible surfaces of proteins (Sayle, R.
A., et al. (1995) Trends Biochem Sci 20:374-376). Structural
analyses that are based on nuclear magnetic resonance measurements
can also be useful in this regard. The fraction of the accessible
sites on the surface with which a particular activated polymer can
react, and the distribution of polymer strands among the various
sites, can be modulated by selecting the appropriate activating
group, the molar ratio of the polymer to the protein and the
appropriate conditions of the coupling reaction (e.g., pH,
temperature, concentrations of reactants, duration of incubation).
In certain circumstances, it can be advantageous to attach the
polymer to residues that are sufficiently far from the active site
of an enzyme to minimize any adverse effects on bioactivity. For
example, the surface of Proteinase K contains many potential sites
for the attachment of polymers that are activated with various
chemistries. However, the previous discovery by some of the present
inventors that the most solvent-accessible lysine residues of
Proteinase K are located exclusively in a region of the enzyme that
is relatively far from the catalytic site makes the use of
amine-reactive polymers especially desirable for this particular
enzyme (see commonly owned, co-pending U.S. patent application Ser.
No. 10/183,607, filed Jun. 28, 2002, which is incorporated herein
by reference in its entirety).
[0108] In certain embodiments (e.g., in the case of enzymes in
which the catalytic domain contains amino groups (such as those
described above) with which the activated polymer can react), it
may be desirable to shield the active site from contact with the
activated polymer. In such cases, the enzyme can be bound tightly,
but reversibly, to a substrate analog or competitive inhibitor that
is sufficiently large to sterically hinder the access of the
activated polymer to reactive residues within or near the active
site (see, e.g., Nahri, L. O., at al. (1991) J Protein Chem
10:385-389). Alternatively, such analogs or inhibitors can be bound
to a solid matrix to which the protein can be subsequently
adsorbed. While hound to the resultant "affinity matrix," the
protein can be reacted with the activated polymer. This strategy
can minimize the coupling of the reactive polymer to sites where
such coupling might inhibit catalysis. The selectively modified
protein can be released from the affinity matrix subsequently, by
methods that are known to those skilled in the art (see Wilchek,
M., et al. (1984) Methods Enzymol 104:3-55). The resultant
conjugates can include protein molecules to which the polymer is
preferentially attached at sites where it does not interfere with
the bioactivity of the protein.
[0109] Following the coupling reaction, conjugates that are
derivatized to various extents can be separated from each other
using size-exclusion and/or ion-exchange chromatography, as
described by Sherman, M. R., et al. (1997) supra. For example,
chromatography on a Superdex.RTM. 75 brand HR 10/30 column or a
Superdex.RTM. 200 brand HR 10/30 column (Amersham Pharmacia
Biotech, Piscataway, N.J.) permits the separation of protein
molecules that are PEGylated to different extents, as well as their
separation from residual free PEG and from most byproducts of the
coupling reaction (see commonly owned, co-pending U.S. patent
application Ser. No. 10/183,607, supra).
Compositions
[0110] The invention provides stabilized conjugates of PEGylated
bioactive components of decreased antigenicity produced by the
methods of this invention. In related aspects, the invention also
provides compositions comprising one or more such conjugates.
Compositions according to this aspect of the invention will
comprise one or more (e.g., one, two, three, four, five, ten, etc.)
of the above-described conjugates of the invention. In certain such
aspects, the compositions may comprise one or more additional
components, such as one or more buffer salts, one or more
chaotropic agents, one or more detergents, one or more proteins
(e.g., one or more enzymes), one or more polymers and the like. The
compositions of this aspect of the invention may be in any form,
including solid (e.g., dry powder) or solution (particularly in the
form of a physiologically compatible buffered salt solution
comprising one or more of the conjugates of the invention).
[0111] Pharmaceutical Compositions
[0112] Certain compositions of the invention are particularly
formulated for use as pharmaceutical compositions for use in
prophylactic, diagnostic or therapeutic applications. Such
compositions will typically comprise one or more of the conjugates
of the invention and one or more pharmaceutically acceptable
carriers or excipients. The term "pharmaceutically acceptable
carrier or excipient," as used herein, refers to a non-toxic solid,
semisolid or liquid filler, diluent, encapsulating material or
formulation auxiliary of any type that is capable of being
tolerated by a recipient animal, including a human or other mammal,
into which the pharmaceutical composition is introduced, without
adverse effects resulting from its addition.
[0113] The pharmaceutical compositions of the invention may be
administered to a recipient via any suitable mode of
administration, such as orally, rectally, parenterally,
intrasystemically, vaginally, intraperitoneally, topically (as by
powders, ointments, drops or transdermal patch), buccally, as an
oral or nasal spray or by inhalation. The term "parenteral" as used
herein refers to modes of administration that include intravenous,
intramuscular, intraperitoneal, intracisternal, subcutaneous and
intra-articular injection and infusion.
[0114] Pharmaceutical compositions provided by the present
invention for parenteral injection can comprise pharmaceutically
acceptable sterile aqueous or nonaqueous solutions, dispersions,
suspensions or emulsions, as well as sterile powders for
reconstitution into sterile injectable solutions or dispersions
just prior to use. Examples of suitable aqueous and nonaqueous
carriers, diluents, solvents or vehicles include water, ethanol,
polyols (such as glycerol, propylene glycol, poly(ethylene glycol),
and the like), carboxymethylcellulose and suitable mixtares
thereof, vegetable oils (such as olive oil), and injectable organic
esters such as ethyl oleate. Proper fluidity can be maintained, for
example, by the use of coating materials such as lecithin, by the
maintenance of the required particle size in the case of
dispersions, and by the use of surfactants.
[0115] Such pharmaceutical compositions of the present invention
may also contain adjuvants such as preservatives, wetting agents,
emulsifying agents and dispersing agents. Prevention of the action
of microorganisms may be ensured by the inclusion of various
antibacterial and antifungal agents, for example, paraben, benzyl
alcohol, chlorobutanol, phenol, sortie acid, and the like. It may
also be desirable to include osmotic agents such as sugars, sodium
chloride and the like. Prolonged absorption of the injectable
pharmaceutical form may be brought about by the inclusion of agents
that delay absorption, such as aluminum monostearate, hydrogels and
gelatin.
[0116] In some cases, in order to prolong the effect of the drugs,
it is desirable to slow the absorption from subcutaneous or
intramuscular injection. This may be accomplished by the use of a
liquid suspension of crystalline or amorphous material with poor
solubility in aqueous body fluids. The rate of absorption of the
drug then depends upon its rate of dissolution, which, in turn, may
depend upon its physical form. Alternatively, delayed absorption of
a parenterally administered drug form is accomplished by dissolving
or suspending the drug in an oil vehicle.
[0117] Injectable depot forms are made by forming microencapsulated
matrices of the drug in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of drug to
carrier polymer and the nature of the particular carrier polymer
employed, the rate of drug release can be controlled. Examples of
other biodegradable polymers include biocompatible
poly(orthoesters) and poly(anhydrides). Depot injectable
formulations are also prepared by entrapping the drug in liposomes
or microemulsions that are compatible with body tissues.
[0118] The injectable formulations can be sterilized, for example,
by filtration through a bacteria-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions that can be dissolved or dispersed in sterile water or
other sterile injectable medium prior to use.
[0119] Solid dosage forms for oral administration include capsules,
tablets, pills, powders and granules. In such solid dosage forms,
the active compounds are mixed with at least one pharmaceutically
acceptable excipient or carrier such as sodium citrate or dicalcium
phosphate and/or a) fillers or extenders such as starches, lactose,
sucrose, glucose, mannitol, and silicic acid, b) binders such as,
for example, carboxymethylcellulose, alginates, gelatin,
polyvinylpyrrolidone, sucrose, and gum acacia, c) humectants such
as glycerol, d) disintegrating agents such as agar-agar, calcium
carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) accelerators of absorption, such as quaternary
ammonium compounds, g) wetting agents such as, for example, cetyl
alcohol and glycerol monostearate, h) adsorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid poly(ethylene glycols), sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0120] Solid compositions of a similar type may also be employed as
fillers in soft- and hard-filled gelatin capsules using such
excipients as lactose (milk sugar) as well as high molecular weight
PEGs and the like.
[0121] The solid dosage forms of tablets, dragees, capsules, pills
and granules can be prepared with coatings and shells such as
enteric or chronomodulating coatings and other coatings well known
in the pharmaceutical formulating art. They may optionally contain
opacifying agents and can also be of such a composition that they
release the active ingredients) only, or preferentially, in a
certain part of the gastrointestinal tract, optionally, in a
delayed manner. Examples of embedding compositions that can be used
include polymeric substances and waxes. The active compounds can
also be in microencapsulated form, if appropriate, with one or more
of the above-mentioned excipients.
[0122] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups and elixirs. In addition to the active compounds, the liquid
dosage forms may contain inert diluents commonly used in the art
such as, for example, water or other solvents, solubilizing agents
and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, PEGs and fatty
acid esters of sorbitan, and mixtures thereof.
[0123] In addition to inert diluents, the oral compositions can
also include adjuvants such as wetting agents, emulsifying and
suspending agents, sweetening, flavoring and perfuming agents.
[0124] Suspensions, in addition to the active compounds, may
contain suspending agents as, for example, ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide, bentonite,
agar-agar, and tragacanth, and mixtures thereof.
[0125] Topical administration includes administration to the skin
or mucosa, including surfaces of the lung and eye. Compositions for
topical administration, including those for inhalation, may be
prepared as a dry powder which may be pressurized or
non-pressurized. In non-pressurized powder compositions, the active
ingredients in finely divided form may be used in admixture with a
larger-sized pharmaceutically acceptable inert carrier comprising
particles having a size, for example, of up to 100 micrometers in
diameter. Suitable inert carriers include sugars such as lactose
and sucrose. Desirably, at least 95% by weight of the particles of
the active ingredient have an effective particle size in the range
of 0.01 to 10 micrometers.
[0126] Alternatively, the pharmaceutical composition may be
pressurized and contain a compressed gas, such as nitrogen or a
liquefied gas propellant. The liquefied propellant medium and
indeed the total composition may be preferably such that the active
ingredients do not dissolve therein to any substantial extent. The
pressurized composition may also contain a surface-active agent.
The surface-active agent may be a liquid or solid non-ionic
surface-active agent or may be a solid anionic surface-active
agent. It is preferable to use the solid anionic surface-active
agent in the form of a sodium salt.
[0127] A further form of topical administration is to the eye. In
this mode of administration, the conjugates or compositions of the
invention are delivered in a pharmaceutically acceptable ophthalmic
vehicle, such that the active compounds are maintained in contact
with the ocular surface for a sufficient time period to allow the
compounds to penetrate the conjunctiva or the corneal and internal
regions of the eye, as for example the anterior chamber, posterior
chamber, vitreous body, aqueous humor, vitreous humor, cornea,
iris/ciliary, lens, choroid/retina and sclera. The pharmaceutically
acceptable ophthalmic vehicle may, for example, be an ointment,
vegetable oil or an encapsulating material.
[0128] Compositions for rectal or vaginal administration are
preferably suppositories that can be prepared by mixing the
conjugates or compositions of the invention with suitable
non-irritating excipients or carriers such as cocoa butter, PEG or
a suppository wax, which are solid at room temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the drugs.
[0129] The pharmaceutical compositions used in the present
therapeutic methods may also be administered in the form of
liposomes. As is known in the art, liposomes are generally derived
from phospholipids or other lipid substances. Liposomes are formed
by mono- or multi-lamellar hydrated liquid crystals that are
dispersed in an aqueous medium. Any non-toxic, physiologically
acceptable and metabolizable lipid capable of forming liposomes can
be used. In addition to one or more of the conjugates or
compositions of the invention, the present pharmaceutical
compositions in liposomal form can also contain one or more
stabilizers, preservatives, excipients, and the like. The preferred
lipids are the phospholipids and the phosphatidyl cholines
(lecithins), both natural and synthetic. Methods to form liposomes
are known in the art (see, e.g., Zalipsky, S., et al., U.S. Pat.
No. 5,395,619). Liposomes that comprise phospholipids that are
conjugated to PEG, most commonly phosphatidyl ethanolamine coupled
to mPEG, have advantageous properties, including prolonged
lifetimes in the blood circulation of mammals (Fisher, D., U.S.
Pat. No. 6,132,763). More advantageously, the hydroxyPEGs of the
present invention may be substituted for mPEG in forming such
PEG-liposomes. Most advantageously, the monofunctionally activated
hydroxyPEGs of the present invention may be substituted for
activated mPEGs in the synthesis of PEG-diacylglycerol that is to
be incorporated into PEG-liposomes.
[0130] Dose Regimens
[0131] The conjugates or compositions of the invention can be
administered in vitro, ex vivo or in vivo to cells to enhance the
cellular response to the active compound(s). One of ordinary skill
will appreciate that effective amounts of a given active compound,
conjugate or composition can be determined empirically and may be
employed in pure form or, where such forms exist, in
pharmaceutically acceptable formulation or prodrug form. The
compounds, conjugates or compositions of the invention may be
administered to an animal or human patient in need thereof as
veterinary or pharmaceutical compositions in combination with one
or more pharmaceutically acceptable excipients. It will be
understood that, when administered to a human patient, the total
daily, weekly or monthly usage of the compounds and compositions of
the present invention will be decided by the attending physician
within the scope of sound medical judgment. The therapeutically
effective dose level for any particular patient will depend upon a
variety of factors including the type and degree of the cellular
response to be achieved; the identity and/or activity of the
specific compound(s), conjugate(s) or composition(s) employed; the
age, body weight or surface area, general health, gender, diet and
activity level of the patient; the time of administration, route of
administration, and rate of excretion of the active compound(s);
the duration of the treatment; other drugs used in combination or
coincidental with the specific compound(s), conjugate(s) or
composition(s); and like factors that are well known to those of
ordinary skill in the pharmaceutical and medical arts. For example,
it is well within the skill of the art to start doses of a given
compound, conjugate or composition of the invention at levels lower
than those required to achieve the desired therapeutic effect and
to gradually increase the dosages until the desired effect is
achieved.
[0132] Dose regimens may also be arranged in a patient-specific
manner to provide a predetermined concentration of a given active
compound in the blood, as determined by techniques accepted and
routine in the art, e.g., size-exclusion, ion-exchange or
reversed-phase HPLC. Thus, patient dose regimens may be adjusted to
achieve relatively constant blood levels, as measured by HPLC,
according to methods that are routine and familiar to those of
ordinary skill in the medical, pharmaceutical and/or
pharmacological arts.
Diagnostic and Therapeutic Uses
[0133] A diagnostic use of a conjugate of the invention might be
for locating an antigenic moiety, e.g., a cancer, within the body
of an animal, especially a human, by administration of a
polymer-conjugated antibody of the invention, in which the
conjugate is labeled on either the protein or polymer component to
enable detection, e.g., by optical, radiometric, fluorescent or
resonant detection as discussed below.
[0134] The PAG-bioactive compound conjugates (preferably
administered as compositions comprising such conjugates) of the
present invention are expected to have much longer circulating half
lives and reduced antigenicity and immunogenicity in vivo. These
properties alleviate or ameliorate the rapid clearance from the
circulation that is observed when many therapeutic compounds
(particularly bioactive compounds such as those that are used as
components in the conjugates of the present invention) are
introduced into an animal, especially a human or other mammal, for
therapeutic purposes. Use of the conjugates and compositions of the
invention also reduces or eliminates concerns about repeated
administration of a particular bioactive compound or component,
which may otherwise provoke an immune response in the patient.
Immune responses of concern include those that neutralize the
bioactivity and/or increase the rate of clearance of the bioactive
compound from the circulation (thereby decreasing the effectiveness
of the diagnostic or therapeutic procedure) and those that cause
adverse effects on the patient.
[0135] Hence, in another aspect of the invention, the conjugates
and compositions of the invention may be used in diagnostic or
therapeutic methods, for example in diagnosing, treating or
preventing a variety of physical disorders in an animal,
particularly a mammal such as a human, predisposed to or suffering
from such a disorder. In such approaches, the goal of the therapy
is to delay or prevent the development of the disorder, and/or to
cure or induce a remission of the disorder, and/or to decrease or
minimize the side effects of other therapeutic regimens. Hence, the
PAG-bioactive component conjugates and compositions of the present
invention may be used for protection, suppression or treatment of
physical disorders, such as infections or diseases. The term
"protection" from a physical disorder, as used herein, encompasses
"prevention," "suppression" and "treatment." "Prevention" involves
the administration of a conjugate or composition of the invention
prior to the induction of the disease or physical disorder, while
"suppression" involves the administration of the conjugate or
composition prior to the clinical appearance of the disease; hence,
"prevention" and "suppression" of a physical disorder typically are
undertaken in an animal that is predisposed to or susceptible to
the disorder, but that is not yet suffering therefrom. "Treatment"
of a physical disorder, however, involves administration of the
therapeutic conjugate or composition after the appearance of the
disease. It will be understood that in human and veterinary
medicine, it is not always possible to distinguish between
"preventing" and "suppressing" a physical disorder. In many cases,
the ultimate inductive event or events may be unknown or latent,
and neither the patient nor the physician may be aware of the
inductive event until well after its occurrence. Therefore, it is
common to use the term "prophylaxis," as distinct from "treatment,"
to encompass both "preventing" and "suppressing" as defined herein.
The term "protection," used in accordance with the methods of the
present invention, therefore is meant to include "prophylaxis."
[0136] Methods according to this aspect of the invention may
comprise one or more steps that allow the clinician to achieve the
above-described therapeutic goals. One such method of the invention
may comprise, for example: [0137] (a) identifying an animal
(preferably a mammal, such as a human) suffering from or
predisposed to a physical disorder; and [0138] (b) administering to
the animal an effective amount of one or more of the compounds or
compositions of the invention as described herein, particularly one
or more PAG conjugates of a bioactive component (or one or more
pharmaceutical compositions comprising such conjugates), such that
the administration of the compounds or compositions prevents,
delays or diagnoses the development of, or cures or induces
remission of, the physical disorder in the animal.
[0139] As used herein, an animal that is "predisposed to" a
physical disorder is defined as an animal that does not exhibit a
plurality of overt physical symptoms of the disorder but that is
genetically, physiologically or otherwise at risk for developing
the disorder. In the present methods, the identification of an
animal (such as a mammal, including a human) that is predisposed
to, at risk for, or suffering from a given physical disorder may be
accomplished according to standard art-known methods that will be
familiar to the ordinarily skilled clinician, including, for
example, radiological assays, biochemical assays (e.g., assays of
the relative levels of particular peptides, proteins, electrolytes,
etc., in a sample obtained from an animal), surgical methods,
genetic screening, family history, physical palpation, pathological
or histological tests (e.g., microscopic evaluation of tissue or
bodily fluid samples or smears, immunological assays, etc.),
testing of bodily fluids (e.g., blood, serum, plasma, cerebrospinal
fluid, urine, saliva, semen and the like), imaging, (e.g.,
radiologic, fluorescent, optical, resonant (e.g., using nuclear
magnetic resonance (NMR) or electron spin resonance (SR)), etc.
Once an animal has been identified by one or more such methods, the
animal may be aggressively and/or proactively treated to prevent,
suppress, delay or cure the physical disorder.
[0140] Physical disorders that can be prevented, diagnosed or
treated with the conjugates, compositions and methods of the
present invention include any physical disorders for which the
bioactive component of the conjugate may be used in the prevention,
diagnosis or treatment. Such disorders include, but are not limited
to, a variety of cancers (e.g., breast cancers, uterine cancers,
ovarian cancers, prostate cancers, testicular cancers, leukemias,
lymphomas, lung cancers, neurological cancers, skin cancers, head
and neck cancers, bone cancers, colon and other gastrointestinal
cancers, pancreatic cancers, bladder cancers, kidney cancers and
other carcinomas, sarcomas, adenomas and myelomas); infectious
diseases (e.g., bacterial diseases, fungal diseases, viral diseases
(including hepatitis and HIV/AIDS), parasitic diseases, and the
like); genetic disorders (e.g., cystic fibrosis, amyotrophic
lateral sclerosis, muscular dystrophy, Gaucher's disease, Pompe's
disease, severe combined immunodeficiency disorder and the like),
anemia, neutropenia, hemophilia and other blood disorders;
neurological disorders (e.g., multiple sclerosis and Alzheimer's
disease); enzymatic disorders (e.g., gout, uremia,
hypercholesterolemia, and the like); disorders of uncertain
etiology (e.g., cardiovascular disease, hypertension, and the
like); and other disorders of medical importance that will be
readily familiar to the ordinarily skilled artisan. The
compositions and methods of the present invention may also be used
in the prevention of disease progression, such as in
chemoprevention of the progression of a premalignant lesion to a
malignant lesion.
[0141] The therapeutic methods of the invention thus use one or
more conjugates of the invention, or one or more of the
pharmaceutical compositions of the invention that may be
administered to an animal in need thereof by a variety of routes of
administration, including orally, rectally, parenterally (including
intravenously, intramuscularly, intraperitoneally, intracistemally,
subcutaneously and intra-articular injection and by infusion),
intrasystemically, vaginally, intraperitoneally, topically (as by
powders, ointments, drops or transdermal patch), buccally, as an
oral or nasal spray or by inhalation. By the invention, an
effective amount of the conjugates or compositions can be
administered in vitro, ex vivo or in vivo to cells or to animals
suffering from or predisposed to a particular disorder, thereby
preventing, delaying, diagnosing or treating the disorder in the
animal. As used herein, "an effective amount of a conjugate (or
composition)" refers to an amount such that the conjugate carries
out the biological activity of the bioactive component of the
conjugate, thereby preventing, delaying, diagnosing, treating or
curing the physical disorder in the animal to which the conjugate
of the invention has been administered. One of ordinary skill will
appreciate that effective amounts of the conjugates or compositions
of the invention can be determined empirically, according to
standard methods well-known to those of ordinary skill in the
pharmaceutical and medical arts; see, e.g., Beers, M. H., et al.,
eds. (1999) Merck Manual of Diagnosis & Therapy, 17th edition,
Merck and Co., Rahway, N.J.; Hardman, J. G., et al., eds. (2001)
Goodman and Gilman's The Pharmacological Basis of Therapeutics,
10th edition, McGraw-Hill Professional Publishing, Elmsford, N.Y.;
Speight, T. M., et al., eds. (1997) Avery's Drug Treatment:
Principles and Practice of Clinical Pharmacology and Therapeutics,
4th edition, Blackwell Science, Inc., Boston; Katzung, B. G. (2000)
Basic and Clinical Pharmacology, 8th edition, Appleton and Lange,
Norwalk, Conn.; which references and references cited therein are
incorporated entirely herein by reference.
[0142] It will be understood that, when administered to a human
patient, the total daily, weekly or monthly dosage of the
conjugates and compositions of the present invention will be
decided by the attending physician within the scope of sound
medical judgment. For example, satisfactory results are obtained by
administration of certain of the conjugates or compositions of the
invention at appropriate dosages depending on the specific
bioactive compound used, which dosages will be readily familiar to
the ordinarily skilled artisan or which may be readily determined
empirically using only routine experimentation. According to this
aspect of the invention, the conjugates or compositions can be
administered once or, in divided doses, e.g., twice per day or per
week or per month. Appropriate dose regimens for various modes of
administration (e.g., parenteral, subcutaneous, intramuscular,
intra-ocular, intranasal, etc.) can also be readily determined
empirically, using only routine experimentation, or will be readily
apparent to the ordinarily skilled artisan, depending on the
identity of the bioactive component.
[0143] In additional applications, the conjugates and compositions
of the invention may be used to specifically target a diagnostic or
therapeutic agent to a cell, tissue, organ or organism that
expresses a receptor for, binds, incorporates or otherwise can take
up, the bioactive component of the conjugate. Methods according to
this aspect of the invention may comprise, for example, contacting
the cell, tissue, organ or organism with one or more conjugates of
the invention, which conjugates additionally comprise one or more
diagnostic or therapeutic agents (preferably covalently linked to
the PAO or PEG component of the conjugate), such that the conjugate
is taken up by the cell, tissue, organ or organism by any mechanism
(e.g., by receptor-mediated endocytosis, pinocytosis, phagocytosis,
diffusion, etc.), thereby delivering the diagnostic or therapeutic
agent to the cell, tissue, organ or organism. The diagnostic or
therapeutic agent used in accordance with this aspect of the
invention may be, but is not limited to, at least one agent
selected from a nucleic acid, an organic compound, a protein, an
antibody, an enzyme, a glycoprotein, a lipoprotein, an element, a
lipid, a saccharide, an isotope, a carbohydrate, an imaging agent,
a detectable probe, or any combination thereof, which also may be
detectably labeled as described herein. A therapeutic agent used in
this aspect of the present invention may have a therapeutic effect
on the target cell (or tissue, organ or organism), the effect being
selected from, but not limited to, correcting a defective gene or
protein, a drug action, a toxic effect, a growth-stimulating
effect, a growth-inhibiting effect, a metabolic effect, a catabolic
affect, an anabolic effect, an antiviral effect, an antifungal
effect, an antibacterial effect, a hormonal effect, a neurohumoral
effect, a cell differentiation stimulatory effect, a cell
differentiation inhibitory effect, a neuromodulatory effect, an
anti-neoplastic effect, an anti-tumor effect, an insulin
stimulating or inhibiting effect, a bone marrow stimulating effect,
a pluripotent stem cell stimulating effect, an immune system
stimulating effect, and any other known therapeutic effect that may
be provided by a therapeutic agent delivered to a cell (or tissue,
organ or organism) via a delivery system according to this aspect
of the present invention.
[0144] Such additional therapeutic agents, which can further
comprise a bioactive conjugate or composition of the present
invention, may be selected from, but are not limited to, known and
new compounds and compositions including antibiotics, steroids,
cytotoxic agents, vasoactive drugs, antibodies and other
therapeutic agents. Non-limiting examples of such agents include
antibiotics and other drugs used in the treatment of bacterial
shock, such as gentamycin, tobramycin, nafcillin, parenteral
cephalosporins, etc.; adrenal corticosteroids and analogs thereof,
such as dexamethasone, which mitigate the cellular injury caused by
endotoxins; vasoactive drugs, such as an alpha adrenergic receptor
blocking agent (e.g., phenoxybenzamine), a beta adrenergic receptor
agonist (e.g., isoproterenol), and dopamine.
[0145] The conjugates and compositions of the invention may also be
used for the diagnosis of disease and to monitor therapeutic
response. In certain such methods, the conjugates of the invention
may comprise one or more detectable labels (such as those described
elsewhere herein). In specific such methods, these detectably
labeled conjugates of the invention may be used to detect cells,
tissues, organs or organisms expressing receptors for, or otherwise
taking up, the bioactive component of the conjugates. In one
example of such a method, the cell, tissue, organ or organism is
contacted with one or more of the detectably labeled conjugates of
the invention under conditions that favor the uptake of the
conjugate by the cell, tissue or organism (e.g., by binding of the
conjugate to a cell-surface receptor or by pinocytosis or diffusion
of the conjugate into the cell), and then detecting the conjugate
bound to or incorporated into the cell using detection means
specific to the label used (e.g., fluorescence detection for
fluorescently labeled conjugates; magnetic resonance imaging for
magnetically labeled conjugates; radioimaging for radiolabeled
conjugates; etc.). Other uses of such detectably labeled conjugates
may include, for example, imaging a cell, tissue, organ or
organism, or the internal structure of an animal (including a
human), by administering an effective amount of a labeled form of
one or more of the conjugates of the invention and measuring
detectable radiation associated with the cell, tissue, organ or
organism (or animal). Methods of detecting various types of labels
and their uses in diagnostic and therapeutic imaging are well known
to the ordinarily skilled artisan, and are described elsewhere
herein.
[0146] In another aspect, the conjugates and compositions of the
invention may be used in methods to modulate the concentration or
activity of a specific receptor for the bioactive component of the
conjugate on the surface of a cell that expresses such a receptor.
By "modulating" the activity of a given receptor it is meant that
the conjugate, upon binding to the receptor, either activates or
inhibits the physiological activity (e.g., the intracellular
signaling cascade) mediated through that receptor. While not
intending to be bound by any particular mechanistic explanation for
the regulatory activity of the conjugates of the present invention,
such conjugates can antagonize the physiological activity of a
cellular receptor by binding to the receptor via the bioactive
component of the conjugate, thereby blocking the binding of the
natural agonist (e.g., the unconjugated bioactive component) and
preventing activation of the receptor by the natural agonist, while
not inducing a substantial activation of the physiological activity
of the receptor itself. Methods according to this aspect of the
invention may comprise one or more steps, for example contacting
the cell (which may be done in vitro or in vivo) with one or more
of the conjugates of the invention, under conditions such that the
conjugate (i.e., the bioactive component portion of the conjugate)
binds to a receptor for the bioactive component on the cell surface
but does not substantially activate the receptor. Such methods will
be useful in a variety of diagnostic, and therapeutic applications,
as the ordinarily skilled artisan will readily appreciate.
Kits
[0147] The invention also provides kits comprising the conjugates
and/or compositions of the invention. Such kits typically comprise
a carrier, such as a box, carton, tube or the like, having in close
confinement therein one or more containers, such as vials, tubes,
ampuls, bottles and the like, wherein a first container contains
one or more of the conjugates and/or compositions of the present
invention. The kits encompassed by this aspect of the present
invention may further comprise one or more additional components
(e.g., reagents and compounds) necessary for carrying out one or
more particular applications of the conjugates and compositions of
the present invention, such as one or more components useful for
the diagnosis, treatment or prevention of a particular disease or
physical disorder (e.g., one or more additional therapeutic
compounds or compositions, one or more diagnostic reagents, one or
more carriers or excipients, and the like), one or more additional
conjugates or compositions of the invention, and the like.
[0148] It will be readily apparent to one of ordinary skill in the
relevant arts that other suitable modifications and adaptations to
the methods and applications described herein may be made without
departing from the scope of the invention or any embodiment
thereof. Having now described the present invention in detail, the
same will be more clearly understood by reference to the following
examples, which are included herewith for purposes of illustration
only and are not intended to be limiting of the invention.
EXAMPLES
Example 1
Preparation and Testing of Antibodies to MonomethoxyPEG
[0149] It has been reported previously that rabbits can be
immunized to various PEGs by immunizing the animals with conjugates
in which PEG was coupled to an immunogenic carrier protein
(Richter, A. W., et al. (1983) Int Arch Allergy Appl Immunol
70:124-131). A monoclonal antibody that reacts with the polyether
backbone of PEG has been developed by injecting mice with an mPEG
conjugate of .beta.-glucuronidase and selecting hybridoma clones
that produce antibodies to PEG (Cheng, T-L., et al. (1999), supra;
Cheng, T L., et al. (2000), supra; Tsai, N.-M., et al. (2001),
supra.; Roffler, S., et al., published U.S. Patent Application No.
2001/0028881 A1 and U.S. Pat. Nos. 6,596,849 and 6,617,118; the
disclosures of all of which are incorporated herein by reference in
their entireties). Another monoclonal antibody that reacts with the
polyether backbone of PEG has been disclosed recently by Roberts,
M. J., et al., in U.S. Patent Application No. 2003/001704 A1.
[0150] In order to develop sensitive methods for the detection of
PEG in PEG-protein conjugates, polyclonal antibodies against PEG
were prepared as described below. Since nearly all PEG conjugates
of therapeutic proteins described in the art have been synthesized
with mPEG, the present inventors investigated the role of the
methoxyl group in the immunoreactivity of conjugates containing
mPEG. The p-nitrophenyl carbonate derivative of 10-kDa mPEG was
custom synthesized by Shearwater Corporation (Huntsville, Ala.), a
subsidiary of Nektar Therapeutics (San Carlos, Calif.). A
urethane-linked mPEG conjugate of a recombinant mammalian uricase
was prepared that contained the minimum number of strands of this
10-kDa mPEG needed to solubilize the protein at physiological pH
(approximately two strands of PEG or mPEG per 35-kDa uricase
subunit). This amount of PEG was not sufficient to suppress the
unusually high immunogenicity of uricase (see Sherman, M. R., et
al., PCT publication WO 01/59078 A2, and Kelly, S. J., et al.
(2001) supra, the disclosures of which are incorporated herein by
reference in their entireties). This PEG-uricase preparation was
injected repeatedly into three rabbits in Freund's adjuvant and the
rabbits were bled for the preparation of antisera containing
polyclonal antibodies against uricase, PEG-uricase conjugates and
PEG.
[0151] Each rabbit was injected with the PEG-uricase preparation
once in complete Freund's adjuvant and five times, at intervals of
one to four weeks, in incomplete Freund's adjuvant. Blood was
sampled approximately two weeks after each of the last three
injections. Serum was prepared from each of the nine blood samples
and small volumes of serum were tested for antibodies against PEG
by an enzyme-linked-immunosorbent-assay ("ELISA"), using 96-well
plates that were coated with mPEG conjugates of a protein that is
structurally unrelated to uricase.
[0152] Each test bleeding yielded antiserum that reacted with PEG
in ELISA analyses. The three rabbits each responded to immunization
with PEG with qualitatively similar kinetics and with similar
specificity for the methoxyl end group of mPEG, as measured by
competitive ELISA. Initially, a dot blot analysis was performed to
determine the sensitivity of the anti-PEG antibodies in the rabbit
sera. Solutions of PEGs of various sizes and structures and the
PEG-uricase solution that was used to immunize the rabbits were
spotted onto a polyvinylidene difluoride blotting membrane
(Invitrogen, Carlsbad, Calif.; catalog #LS2002). After blocking the
membrane with a solution of 2% (w/v) non-fat dry milk powder, the
membrane was incubated with a dilution of the rabbit antiserum to
PEG-uricase that was prepared as described above. Then a dilution
of anti-rabbit IgG antibodies produced in goats and coupled to
alkaline phosphatase (Calbiochem, San Diego, Calif.; catalog
#401371) was applied as a secondary antibody. Alkaline phosphatase
activity on the blot was detected using a combination of
5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium
(Sigma, catalog #B-1911), as described previously (Blake, M. S., et
al. (1984) Anal Biochem 136:175-190, the disclosures of which are
incorporated herein by reference in their entirety). With high
sensitivity and specificity, the rabbit anti-PEG antibodies
detected the PEG solutions and the mPEG-protein conjugate that were
tested.
Example 2
Demonstration of the Role of the Methoxyl Group in the Antigenicity
of mPEG
[0153] Unexpectedly, the present inventors have found that the
anti-PEG antibodies prepared as described in Example 1 were
directed predominantly against the methoxyl end group of the mPEG
component of the antigen. FIG. 1 depicts the results from a
competitive ELISA assay in which 96-well plates were coated with an
mPEG conjugate of a protein that is structurally unrelated to
uricase. After blocking the plate with 2% goat serum, solutions of
increasing concentration of 4.8-kDa mPEG (Polymer Laboratories,
catalog #6570-5010), 10-kDa mPEG (Union Carbide, catalog
#MPEG-10,000) or 10-kDa t-butoxyPEG (Polymer Laboratories, catalog
#29999997) were added and incubated with a 1:1,000 dilution of
rabbit antiserum formed against the mPEG-uricase conjugate. After
removing the solution, the extent of anti-PEG antibody bound to the
mPEG-protein conjugate on the plate was measured
spectrophotometrically, using a peroxidase-conjugated secondary
antibody (goat anti-rabbit IgG, Calbiochem.RTM., San Diego, Calif.;
catalog #401393) followed by the addition of the peroxidase
substrate, o-phenylenediamine dihydrochloride (Sigma, St. Louis,
Mo.; catalog #P-9781). For each sample, the initial reaction rate
(in milli-absorbance units per minute) observed in the absence of a
competitor was designated as 100%. The overlapping curves of the
two solutions of mPEG suggest that the length of the PEG backbone
is not the predominant determinant of its antigenicity. The curve
for t-butoxyPEG is shifted to the right by approximately 2 log
units, indicating that t-butoxyPEG has about a 100-fold lower
affinity than mPEG for antibodies generated against an mPEG-protein
conjugate. In previous unpublished experiments by certain of the
present inventors, however, it was found that t-butoxyPEG displays
significant immunogenicity when conjugated to an immunogenic
protein. Thus, while FIG. 1 demonstrates very little
cross-reactivity of t-butoxyPEG with antibodies raised against
mPEG, the use of t-butoxyPEG instead of mPEG in the production of
PEGylated therapeutic proteins would not solve the problem of the
immunogenicity of the PEG component.
[0154] The results depicted in FIG. 1 suggest that the methoxyl
group on mPEG is the predominant antigenic group on the polymer
molecule. To confirm this inference, the antibodies generated as
described in Example 1 were subjected to competitive ELISA
analysis, performed as described for FIG. 1, using PEGs of various
sizes and structures containing one or two methoxyl groups. FIG. 2a
displays the results for antibody binding, graphed as a function of
the molar concentration of methoxyl groups in each sample. The
concentration of competitor resulting in 50% inhibition of the
binding ("IC.sub.50") was calculated using the equation for a
5-parameter sigmoid curve and the program SigmaPlot.RTM., (SPSS
Science, Chicago, Ill.).
[0155] As shown in FIG. 2a, the following PEGs were all similarly
antigenic on a molar basis: linear PEGs with one methoxyl group
("10-kDa mPEG"), prepared by hydrolysis of mPEG-NPC (PEG-Shop) and
"mono-20-kDa mPEG-lysine," synthesized by coupling lysine to 20-kDa
NPC-PEG (Shearwater, catalog #M-NPC-20,000); a linear PEG with two
methoxyl groups ("Bis-(2-kDa) mPEG" (Sigma-Aldrich, catalog
#81314)), and a large "branched" PEG containing two methoxyl groups
("Di-(20-kDa) mPEG-lysine" (Shearwater, catalog #PEG2-NHS-40K)). In
contrast, the curve for the smaller "branched" PEG with two
methoxyl groups ("Di-(5-kDa) mPEG-lysine" (Shearwater, catalog
#2Z3X0L01)) was shifted to the left of the mean of the results for
the other samples by 0.5 to 0.6 log units, indicating that this
form of "branched" mPEG is three to four times as antigenic as the
other samples tested in this experiment. FIG. 2b displays the data
from FIG. 2a as a function of the weight concentration of mPEG
(microgram/mL) instead of the molar concentration of methoxyl
groups, supporting the conclusion that it is the methoxyl group
that is critical for the interaction of mPEG with the anti-mPEG
antibodies.
[0156] FIG. 3 displays a subset of the data from FIGS. 1, 2a and 2b
in a format that demonstrates the direct dependence of the
antigenicity on the number of methoxyl groups per molecule of PEG.
These samples represent 10-kDa PEGs with no methoxyl group ("10-kDa
t-butoxyPEG"), with one methoxyl group ("10-kDa mPEG") or with two
methoxyl groups ("Di-(5-kDa) mPEG-lysine"). The results indicate
that the antigenicity of a given polymer, and thus of a conjugate
of the invention produced with this polymer, is directly dependent
upon the number of methoxyl groups contained on the PEG polymer
molecule. The larger the number of methoxyl groups, the higher the
affinity of the polymer for the antibodies raised against an
mPEG-protein conjugate.
[0157] Taken together, these results indicate that complete
inhibition of the binding of the rabbit antibodies to an mPEG
conjugate could be accomplished by competition with solutions of
PEG, and especially of mPEG. Moreover, the ability of solutions of
mPEGs to block the binding of the rabbit anti-PEG antibodies to
mPEG conjugates of an unrelated protein is correlated with their
content of methoxyl groups. On the basis of concentration by
weight, mPEGs of lower molecular weight were more potent
competitors than mPEGs of higher molecular weight, as shown in FIG.
2b. This conclusion is consistent with the fact that the ratio of
the mass of the methoxyl groups to the total mass of the polymer
decreases as the molecular weight of the polymer increases. Among
the PEGs that were tested, the most potent antigens (on a molar
basis) were the "branched" PEGs containing two methoxyl groups,
which are sometimes referred to as umbrella-like or "U-PEGs"
(Martinez, A., et al., U.S. Pat. No. 5,643,575) or as "Y-PEGs"
(Greenwald, R. B., et al. published U.S. Patent Application No.
2002/0052443 A1).
Example 3
Testing of Anti-PEG Antibodies with PEGs Lacking Methyoxyl
Groups
[0158] The term "PharmaPEG" is used herein to refer to linear or
branched PEGs lacking an antigenic group at the terminus or termini
that is or are distal from the terminus that is activated or can be
activated. From the previous examples, it can be inferred that the
antigenicity of a polymer, and therefore of a polymer conjugate of
a bioactive agent, is a function of the content of methoxyl groups
in the polymer. To further test this inference, competitive ELISA
analyses were performed, as described for FIG. 1, comparing the
abilities of mPEG ("4.8-kDa mPEG") and 12-kDa, 20-kDa and 35-kDa
PharmaPEGs, which have no methoxyl groups or other alkoxyl groups
at the ends of the linear polymers, to be bound by anti-mPEG
antibodies. Results are shown in FIG. 4. The shift of the three
PharmaPEG curves relative to the mPEG curve depicted in FIG. 4
indicates that the antigenicity of PharmaPEG is approximately
100-fold lower than that of mPEG, when assayed with anti-mPEG
antibodies. Hence, polymers lacking methoxyl groups (e.g.,
PharmaPEG) are reduced or substantially reduced in antigenicity
when compared to the polymers that are traditionally used for
bioconjugation of pharmaceuticals, e.g., mPEG.
[0159] As noted above, on a weight basis, the competitive potencies
of mPEGs are inversely proportional to their molecular weights.
However, PEGs lacking methoxyl groups had only about 1% of the
competitive potencies of mPEGs, independent of their molecular
weights. These results support the conclusion that monofunctionally
reactive polymers lacking methoxyl groups are particularly well
suited for use in preparing polymer conjugates of bioactive agents
that have reduced, substantially reduced, or no antigenicity
compared to conjugates produced using mPEGs, especially "branched"
mPEGs, such as di-mPEG-lysine.
Example 4
Detection of PEGylated Protein Conjugates by Western Blots with
Anti-mPEG Antibodies
[0160] MonomethoxyPEG conjugates of carbonic anhydrase (EC 4.2.1.1;
"CA II") were used as models in testing the ability of the
anti-mPEG antibodies to detect PEGylated protein conjugates
following polyacrylamide gel electrophoresis in the presence of
sodium dodecyl sulfate ("SDS-PAGE"). Gels were electroblotted onto
a polyvinylidene difluoride membrane and the blots were incubated
with rabbit anti-mPEG antibodies (diluted 1:200), followed by
incubation with a secondary antibody (goat anti-rabbit IgG)
conjugated to alkaline phosphatase and exposure to a substrate that
forms a colored precipitate. This method of immunologic detection
of proteins or polymer-protein conjugates transferred from an
electrophoretic gel to a membrane is commonly referred to as a
"Western blot" (Tsang, V. C. W., et al., (1984) Anal Biochem
143:304-307). The detection procedure and reagents were the same as
those described for the dot blots in Example 1. The results are
shown in FIG. 5a. Lanes 1 and 2 show a gel stained for protein
using SYPRO.RTM. brand Ruby Stain (Molecular Probes, Eugene, Oreg.,
catalog #S-12000) and photographed with a Kodak digital camera,
using an Orange/Red visible light filter (Molecular Probes, catalog
#S-6655) in a dark hood with illumination at 302 nm. Lanes 3 and 4
show the results of a Western blot of the same samples. Anti-mPEG
antibodies are seen in the positions of all of the PEGylated
species (Lane 3) but not of the unmodified carbonic anhydrase (Lane
4).
[0161] FIG. 5b shows the quantitation of band intensities in the
gel and Western blot shown in FIG. 5a, obtained with Kodak 1D
Imaging Analysis software (Kodak, Rochester, N.Y.). The horizontal
axis represents the migration distance relative to the dye front
and the vertical axis represents the relative intensities of the
protein stain or anti-mPEG stain. The bottom tracing shows bands of
SeeBlue Plus2.TM. brand pre-stained standard proteins (Invitrogen
Corporation, Carlsbad, Calif.; catalog #LC5625), in which the peaks
numbered 1 through 8 identify proteins with the following apparent
molecular weights (in kDa): 204, 111, 68.8, 51.5, 40.2, 28.9, 20.7
and 14.9, respectively. The second tracing from the bottom is an
anti-mPEG antibody stain of PEGylated carbonic anhydrase. The third
tracing from the bottom represents the protein-stained band of
carbonic anhydrase and the top tracing shows the protein-stained
mPEG conjugates of carbonic anhydrase. The numbers above the peaks
in FIG. 5b indicate the numbers of mPEG strands coupled to carbonic
anhydrase in the conjugate(s) in that peak. PEG.sub.0 indicates the
position of carbonic anhydrase to which no PEG is coupled.
[0162] Together, these results indicate that anti-mPEG antibodies
are able to form complexes readily with PEGylated proteins prepared
with a reactive form of mPEG, and thereby allow their sensitive and
selective detection. When such conjugates are introduced into an
animal for diagnostic, prophylactic or therapeutic purposes, the
induction of anti-mPEG antibodies would contribute to an
accelerated rate of clearance of the agent from the bloodstream,
thereby limiting the efficacy of those conjugates and potentially
leading to adverse effects mediated by the formation of immune
complexes.
Example 5
Synthesis of PharmaPEG-Mononitrophenyl Carbonate
[0163] A requirement for preparing monofunctionally activated
PharmaPEG from PEG diol is that, at some step in the synthesis, one
of the terminal groups of the PEG must have properties that allow
the separation of PEGs containing different numbers of that
terminal group. Such a group might be more hydrophobic than either
PEG or activated PEG, allowing the separation by reversed-phase
chromatography ("RP chromatography"). Alternatively, such a group
might be charged, permitting separation by ion-exchange
chromatography. Such a group might be part of a solid phase,
allowing phase separation from liquids in which the unbound PEG is
soluble. If the activating group can be used as the basis of the
separation, as in the case of NPC-PEG described in this Example 5,
then the attachment of the activating group is the only synthetic
reaction needed. If a removable blocking group, e.g., a t-butyl or
triphenylmethyl ("trityl") group, provides the basis of the
separation, the blocking group can be added either before or after
the attachment of the activated or activatable group, as described
in Example 6. In theory, the purification step used to isolate PEG
containing the desired number of blocking groups can be performed
at any time after the blocking group is attached. In practice, the
relative labilities of the bonds between the polymer backbone and
the blocking group and between the polymer backbone and the
activating (or activatable) group may dictate the optimal sequence
of the steps.
[0164] The synthesis of monofunctionally activated NPC-PEG from
dihydroxyPEG is summarized in the following diagram, in which Ph
denotes a phenyl group and n denotes the number of ethylene oxide
units in the polymer, which is about 227 for 10-kDa PEG.
##STR00002##
[0165] PEG diols from several suppliers, all of which were labeled
as having molecular weights of 10 kDa, were tested for purity and
homogeneity. None of them contained more than 90% of PEG with a
molecular weight of about 10 kDa. Therefore, 10-kDa PEG diol (Fluka
Chemical Corp., Milwaukee, Wis., catalog #81280) was fractionated
from contaminants of lower molecular weight by reversed-phase
chromatography on an Amberchrom MD-P CG-300SD column (7.5
mm.times.15 cm, TosoHaas, Montgomeryville, Pa.). PEG was loaded
onto the column as a solution in 5% (v/v) acetonitrile in water and
was eluted with a linear gradient of 5% to 35% acetonitrile in
water. Fractions were analyzed by size-exclusion chromatography on
a Superdex.RTM. 200 brand HR10/30 column (Amersham Pharmacia
Biotech, Piscataway, N.J.) in 20 mM sodium acetate containing 150
mM NaCl, pH 4.6. Fractions from the Amberchrom column in which more
than 98% of the refractive index ("RI") signal due to PEG was in
the peak corresponding to about 10-kDa PEG were pooled and
lyophilized.
[0166] The purified, dried PEG diol (530 mg) was combined with 61.4
mg p-nitrophenyl chloroformate (Aldrich, Milwaukee, Wis., catalog
#16, 021-0) and dissolved in 4 mL acetonitrile in a screw-capped
13.times.100 mm glass tube, giving final concentrations of about
12.5 mM PEG diol and about 75 mM p-nitrophenyl chloroformate.
Pyridine (0.25 g) was added and the reaction mixture was incubated
overnight at 36.degree. C. The reaction was quenched by stirring
the mixture into 33 mL of ice-cold 0.1 M hydrochloric acid. The
solution was filtered to remove a slight precipitate of
p-nitrophenol and was dialyzed for one day in the cold against four
1-L changes of water. Acetonitrile was added to the dialyzed
solution to bring the concentration to 5% (v/v). Half of the
mixture produced in Step 1 (24 mL), which contained about 265 mg of
the purified 10-kDa PEG diol, was loaded onto the Amberchrom column
and the bound PEG species were eluted with a gradient of 5% to 65%
acetonitrile in water. Fractions were analyzed by size-exclusion
chromatography as before, monitoring both the refractive index and
absorbance at 280 nm. DihydroxyPEG, which lacked absorbance at 280
nm, was eluted first, followed by PEG derivatized with a single
p-nitrophenyl group ("mono-NPC PEG"), followed by di-NPC PEG, for
which the ratio of absorbance at 280 nm to the refractive index was
twice that of mono-NPC-PEG. Two fractions in the center of the
mono-NPC PEG elution range were combined to give about 110 mg of
mono-NPC PEG, corresponding to a yield of about 42%. The product of
Step 2 could be dried for storage in a desiccator and/or a freezer
or used directly for coupling to an amine-containing bioactive
compound or to a linker containing two or more amino groups for the
preparation of branched PEGs, e.g., diPEG-lysine, which contained
no alkoxyl groups.
Example 6
Synthesis of a PharmaPEG-Monoaldehyde from PEG Diol
[0167] The synthesis of the monopropionaldehyde derivative of
PharmaPEG is summarized in the following diagram, in which KOtBu
denotes potassium t-butoxide, and DEP denotes the
3,3-diethoxypropyl group,
##STR00003##
[0168] Preferably, the dihydroxyPEG that is used as starting
material for Step 1 will have a molecular weight that is within 10%
of its nominal molecular weight and will have a polydispersity of
<1.05. Polydispersity is defined as the ratio of the
weight-average molecular weight ("M.sub.w") to the number-average
molecular weight ("M.sub.n"). Both of these parameters, M.sub.w and
M.sub.n, can be measured by size-exclusion chromatography, using
PEGs of accurately known molecular weights as standards and gel
permeation chromatography software such as EZChrom Elite
Client/Server Software, Version 2.8.3 (Scientific Software, Inc.,
Pleasanton, Calif.). Alternatively, the polydispersity of PEGs can
be measured by matrix-assisted laser desorption/ionization
time-of-flight ("MALDI-TOF") mass spectroscopy (Marie, A., et al.,
(2000) Anal Chem 72:5106-5114), using software such as Voyager
Software (Applied Biosystems, Foster City, Calif.). For the
preparation of pharmaceutical products containing covalently linked
PEG, the PEG starting material will preferably have a
polydispersity of <1.02, and more preferably <1.01, when
measured by MALDI-TOF mass spectroscopy. The starting material may
be obtained from Aldrich Chemical Co., Fluka Chemicals (Buchs,
Switzerland), Shearwater Corporation or from Sigma Chemical Co.,
among other suppliers that are known to those skilled in the art.
If the starting material is not sufficiently homogeneous, it can be
fractionated by an adaptation of the method described in Example
5.
[0169] A mixture of monopropionaldehyde and dipropionaldehyde
diethyl acetal derivatives of PEG diol can be synthesized using
3-chloro-propionaldehyde diethyl acetal (Aldrich catalog
#C6,900-4), as described for acetaldehyde diethyl acetal by Harris,
J. M., et al., ((1984) J Polym Sci 22:341-352) (see Step 1).
Similar methods were also described by Bentley, M. D., et al.,
((1998) J Pharm Sci 87:1446-1449) and were subsequently patented by
Bentley, M. D., et al. (U.S. Pat. No. 5,990,237).
[0170] A sufficient quantity of triphenylmethyl chloride
(chlorotriphenyl-methane or trityl chloride, Ph.sub.3CCl, e.g.,
Aldrich catalog #T8, 380-1) dissolved in pyridine is added to the
mixture produced in Step 1 so that, under the reaction conditions,
the Ph.sub.3CCl will react with all of the hydroxyl groups of the
PEG starting material that are not coupled to the propionaldehyde
diethyl acetal (Kocienski, P. J., supra). To complete Step 2, the
mixture is recovered after precipitation by the addition of a poor
solvent for PEG (e.g., ether) or by evaporation of the solvent or
by other methods that are known in the art.
[0171] The mixture recovered from Step 2 is dissolved in water
before or after the addition of 5% (v/v) acetonitrile and the
solution is loaded onto a reversed-phase column that is expected
from principles known in the art to be capable of binding trityl
derivatives of PEG. The column may contain alkyl or aryl
derivatives of silica or a polymeric substrate, or it may be a
styrene-based polymer (e.g. Amberchrom MD-P CG-300), as in Example
5. The PEG diol and trityl derivatives can be eluted in a
reversed-phase mode with an increasing gradient of organic solvent,
as in Example 5, or in a sample displacement mode by continuing to
load the column until at least a portion of the desired species has
been eluted (Agner, E., et al., PCT publication WO 00/23798 A1) or
in displacement mode (Cramer, S. M., U.S. Pat. No. 6,239,262), or
in a combination of these modes. In general, the PEG derivative
lacking any trityl group will elute first, the monotrityl
derivative will elute second and the ditrityl PEG will elute third.
An optimal yield of the desired product is obtained when the ratios
of these three species are 1:2:1. To improve the yield and/or
purity of the desired monotrityl PEG product, it may be desirable
to subject a portion of the column effluent to recycling
chromatography, as is well known in the chromatographic art. To
complete Step 3, the portion of the eluate that contains at least a
portion of the monotrityl derivative is separated, concentrated and
dried by methods that are known in the art.
[0172] Under mildly acidic conditions and at low temperature, the
acetal can be converted to the aldehyde, while preserving most of
the trityl linkage at the distal end of the PEG. In some
applications of this example, it may be advantageous to react the
monotrityl PEG monoaldehyde with a target moiety before removing
the trityl group. Such embodiments are envisioned by and included
in the present invention.
Example 7
Demonstration of the Decreased Immunogenicity of Conjugates
Prepared with HydroxyPEG Compared with MethoxyPEG
[0173] Proceeding as described for immunization with mPEG
conjugates of uricase, as in Example 1, groups of three rabbits
were immunized with either mPEG conjugates or hydroxyPEG conjugates
of the same preparation of porcine uricase, each containing an
average of about two strands of 10-kDa PEG per uricase subunit. The
average number of strands of polymer attached to each preparation
of conjugates was confirmed by both size-exclusion HPLC analyses
and by SDS-PAGE, in which the gels were stained both for protein,
as in Example 4, and for PEG, using the method described in
commonly owned co-pending U.S. patent application Ser. No.
10/183,607, filed Jun. 28, 2002, which is incorporated herein by
reference in its entirety. Each rabbit was injected with one of the
PEG-uricase preparations once in complete Freund's adjuvant and
five times, at intervals of one to four weeks, in incomplete
Freund's adjuvant. Blood was drawn two weeks after the fourth and
fifth injections in incomplete Freund's adjuvant and sera were
prepared. When serial 4-fold dilutions of the sera from these
rabbits were tested by ELISA analyses, as in Example 2, the
concentration of anti-PEG antibodies that was induced by the
conjugates prepared with hydroxyPEG was found to be less than 5% of
that induced by the conjugates prepared with mPEG (see FIGS. 6a and
6b). In contrast, the induction of anti-uricase antibodies by the
conjugates prepared with the two types of PEG was similar in the
two groups of rabbits. None of the preimmunization sera from these
rabbits contained detectable anti-PEG antibodies.
Discussion and Conclusions
[0174] It has been reported in the art that PEG terminated in a
methoxyl group (mPEG) and PEG terminated in a hydroxyl group
(bis-hydroxyPEG or PEG diol) are equivalent for use in
bioconjugation, or, more often, that mPEGs and other lower alkoxyl
PEGs are superior to PEG diols. Moreover, bis-activated diols can
act as cross-linking agents, which can be undesirable for producing
soluble, long-acting bioconjugates of low immunogenicity and
antigenicity. Surprisingly, the results of the present studies
indicate that mPEGs are significantly antigenic, and that
antibodies induced against the methoxyl group of mPEG bind to
PEGylated protein conjugates prepared using mPEG. Hence,
unexpectedly and contrary to previous reports, mPEG is not
equivalent to hydroxyPEG and mPEG is not preferred for preparing
polymer conjugates of bioactive components (such as proteins) that
are intended to have increased bioavailability, stability in the
blood circulation and minimal immunogenicity.
[0175] Based on the present results, it is clear that the use of
monofunctionally activated PEG that does not contain a methoxyl
group or another alkoxyl group for the synthesis of protein
conjugates results in conjugates with decreased immunoreactivity.
The resultant conjugates have been demonstrated to have decreased
antigenicity, i.e., decreased ability to interact with antibodies
developed against mPEG conjugates of the same protein, and
decreased immunogenicity, i.e., decreased ability to evoke an
immune response against the PEG component. As a corollary,
conjugates prepared with branched PEGs containing two or more
methoxyl groups are expected to be more immunogenic than conjugates
prepared from branched PEGs lacking alkoxyl groups.
[0176] Finally, based on the present findings, the use of
monofunctionally activated PEG that does not contain a methoxyl
group or another alkoxyl group, rather than monofunctionally
activated mPEG, for the synthesis of PEG-liposomes is expected to
confer on the resulting PEG-liposomes a decreased immunoreactivity,
including a decreased tendency to trigger the activation of
complement in blood, and a decreased tendency to induce acute
respiratory distress or anaphylactoid and pseudo-allergic
reactions.
[0177] This invention is described herein with reference to certain
embodiments thereof. The methods of this invention are similarly
applicable to other types of proteins, to other bioactive agents
and to other conjugation reagents. Therefore, the scope of this
invention is not limited to the embodiments described, but is
limited only by the scope of the claims and/or equivalents thereof.
Workers of ordinary skill in the art can readily appreciate that
other embodiments can be practiced without departing from the scope
of this invention. All such variations are considered to be part of
this invention.
[0178] All publications, patents and patent applications mentioned
in this specification are indicative of the level of skill of those
skilled in the art to which this invention pertains, and are herein
incorporated by reference to the same extent as if each individual
publication, patent or patent application was specifically and
individually indicated to be incorporated by reference.
* * * * *